| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Eledon Pharmaceuticals, Inc.$3.85
-0.28 (-6.78%)
D 31Pipeline Score Overvalued Pharma · Clinical
Market Cap
300.26 M
EPS
-0.86
P/E Ratio
-
Value Trade
3.70 M
SEC Financials
Q1 2026Dilution Risk
25%R&D Expenses
17.20 M
Operating CF
-22.61 M
Total Assets
146.67 M
Total Liabilities
46.21 M
Equity
44.76 M
D/E Ratio
12,345
-0.26 %
Week
-2.75 %
1 Month
73.66 %
3 Month
177.86 %
6 Month
-59.39 %
5 Year
-99.87 %
All Time
Cash Data
Cash Position
111.09 M
Monthly Burn
7.54 M
Runway
12.7 mo
Burn Trend
SEC Filing
May 13, 2026
Overview
Volume
1.39 M
52 Week Range
1.35 - 4.60
% held by Insiders
4.45 %
% held by Institutions
57.89 %
Enterprise Value
245.42 M
Total Shares
77.17 M
Short %
10.15 %
Float Shares
77.17 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Eledon Pharmaceuticals, Inc.
367Total events
3Upcoming
74Tier-1 (high impact)
2016 – 2026Coverage
Upcoming catalysts 3
Event history 364
Jun 22, 2026
◆Oral PresentationtegoprubartPresentation
Oral presentation of Phase 2 BESTOW trial data at ATC
kidney transplantationsource ↗
Jun 22, 2026
◆Quarterly UpdatetegoprubartCorporate
Conference call to discuss updated BESTOW data and long-term extension data
kidney transplantationsource ↗
Jun 20, 2026
◆Poster PresentationtegoprubartPresentation
Poster presentation of Phase 2 BESTOW extension trial long-term data at ATC
kidney transplantationsource ↗
Jun 7, 2026
◆Oral PresentationtegoprubartPresentation
Oral presentation of updated data from investigator-initiated islet transplant trial of tegoprubart at ADA 2026
Type 1 Diabetessource ↗
Jun 5, 2026
▲Oral PresentationtegoprubartPresentation
Updated results from investigator-initiated islet transplant trial presented at ADA 86th Scientific Sessions
type 1 diabetessource ↗
May 13, 2026
▲Orphan Drug DesignationtegoprubartDesignation
FDA Orphan Drug designation granted for tegoprubart in liver transplantation
prevention of allograft rejection in liver transplantationsource ↗
Mar 19, 2026
▲Full ResultstegoprubartClinical Data
Reported updated results from 12 patients with type 1 diabetes treated with tegoprubart following islet transplantation
type 1 diabetes (islet transplantation)source ↗
Mar 19, 2026
▲Orphan Drug DesignationtegoprubartDesignation
Tegoprubart granted Orphan Drug designation by FDA for prevention of allograft rejection in liver transplantation
prevention of allograft rejection in liver transplantationsource ↗
Mar 19, 2026
Mar 16, 2026
Mar 11, 2026
◆Oral PresentationPresentation
Eledon Pharmaceuticals to participate in fireside chat at Leerink Partners 2026 Global Healthcare Conference
Drug Pipeline Intelligence
D31
Pipeline Score $49M
Pipeline ValueOvervalued
Valuation Signal1
Drugs Scored0.2x
rNPV / MCap Top 38%
Micro Cap (rank 566 of 912)
Percentile RankEledon Pharmaceuticals, Inc. faces pipeline headwinds (31/100), with $283M risk-adjusted pipeline value, led by AT-1501 in Prevention of Rejection in Kidney Transplant (Phase 1).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AT-1501 Small molecule | Kidney Transplant Rejection | Phase 2 | NCT05983770 | 16% | $283M | COMPLETED | 259 | - | - | Sep 25, 2025 | ELEVATED_RISK | Oct 29, 2025 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
tegoprubart Orphan | Type 1 Diabetes | — | 2026-06-08 | insulin independence: 100%; mean Hb A1c: 5.4%; Hb A1c improvement: approximately 2.6%; no severe hypoglycemic events: true Read More | Eledon Announces Updated Data from Investigator-Initiated Islet Transplant Trial of Tegoprubart in Patients with Type 1 Diabetes (T1D) at UChicago Medicine Read More | |
tegoprubart Orphan | Type 1 Diabetes | — | 2026-06-08 | insulin independence: 100%; mean Hb A1c: 5.4%; Hb A1c improvement: approximately 2.6%; no severe hypoglycemic events: true Read More | Eledon Announces Updated Data from Investigator-Initiated Islet Transplant Trial of Tegoprubart in Patients with Type 1 Diabetes (T1D) at UChicago Medicine Read More | |
tegoprubart Orphan | Type 1 Diabetes | — | 2026-06-08 | insulin independence: 100%; mean Hb A1c: 5.4%; Hb A1c improvement: approximately 2.6%; no severe hypoglycemic events: true Read More | Eledon Announces Updated Data from Investigator-Initiated Islet Transplant Trial of Tegoprubart in Patients with Type 1 Diabetes (T1D) at UChicago Medicine Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in ELDN
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
ELDN Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
ELDNDiabetes Dialogue: Tegoprubart and Freedom from Insulin in Type 1 Diabetes
The article discusses the ongoing dialogue surrounding Tegoprubart, a potential treatment for Type 1 Diabetes. It highlights the significance of patient stories and clinical trials in understanding the impact of this therapy. However, the article lacks specific details on trial results or regulatory updates.
Read more →ELDNWhy Natera’s Prospera could reshape how Eledon measures kidney transplant injury in Phase 3
The article discusses how Natera's Prospera test could significantly impact Eledon's approach to measuring kidney transplant injury during Phase 3 trials. It highlights the potential benefits of integrating this technology into clinical practice. However, specific details on the implications or outcomes of this integration are not provided.
Read more →ELDN▼ -5.7%on this newsshared move
Drug to prevent organ rejection after kidney transplant tops standard treatment in trial
A new drug developed to prevent organ rejection after kidney transplants has demonstrated superior efficacy compared to standard treatments in recent clinical trials. This advancement could significantly enhance patient outcomes and transform post-transplant care. The results indicate a promising future for patients receiving kidney transplants.
Read more →ELDNEledon Announces Updated Data from Investigator-Initiated Islet Transplant Trial of Tegoprubart in Patients with Type 1 Diabetes (T1D) at UChicago Medicine
Eledon Pharmaceuticals announced positive outcomes from a trial of tegoprubart, showing all 12 participants with type 1 diabetes achieved insulin independence and had significantly improved HbA1c levels. The study also reported no severe hypoglycemic events post-transplantation. The results suggest a potential advance in islet transplantation approaches, reducing reliance on traditional immunosuppressants like tacrolimus. Eledon aims to work with the FDA for guidance on a pathway to market for tegoprubart in this context.
Read more →ELDN▼ -5.3%on this newsshared move
The CEO Who Wants to Make Tacrolimus History
The article discusses the vision of the CEO of Eledon Pharmaceuticals, who aims to revolutionize the use of Tacrolimus in organ transplantation. It highlights the company's commitment to improving patient outcomes through innovative therapies. However, specific details about ongoing projects or clinical trials are not provided.
Read more →ELDNEledon Announces Presentation of Updated Data from Investigator-Initiated Islet Transplant Trial of Tegoprubart in Patients with Type 1 Diabetes at American Diabetes Association (ADA) 2026 Scientific Sessions
Eledon Pharmaceuticals announced that updated results from an investigator-initiated trial of tegoprubart will be presented at the 2026 American Diabetes Association Scientific Sessions. The presentation, led by Dr. Piotr Witkowski, will focus on the use of anti-CD40L to enhance graft survival in islet allotransplantation. This highlights Eledon's efforts in developing immune-modulating therapies for type 1 diabetes. The conference takes place from June 5-9 in New Orleans, Louisiana.
Read more →ELDN▲ +7.3%on this news
Eledon Pharmaceuticals to Present New Long-Term Data from Phase 2 BESTOW Trial of Tegoprubart for the Prevention of Rejection in Kidney Transplantation at American Transplant Congress
Eledon Pharmaceuticals announced that it will present new long-term clinical data from its tegoprubart program at the upcoming American Transplant Congress from June 20-24, 2026. This will include updated findings from the Phase 2 BESTOW trial and an extension study focused on preventing kidney transplant rejection. The presentations will feature expert input from Andrew Adams, M.D., Ph.D., highlighting the significance of tegoprubart in transplantation therapies. Following the presentations, a conference call will provide further insights into the data shared at the Congress.
Read more →ELDNThe Greatest Women’s Health Breakthroughs of 2026: New Research That Could Change Your Year
The article discusses significant advancements in women's health expected in 2026, highlighting various research initiatives and clinical trials. It emphasizes the transformative potential of these breakthroughs on patient care and health outcomes. The content also touches on the importance of ongoing research and development in the field of women's health.
Read more →ELDNEledon Pharmaceuticals Reports First Quarter 2026 Financial Results and Recent Business Highlights
Eledon Pharmaceuticals reported its first quarter 2026 financial results, highlighting significant advancements in its tegoprubart program. Notably, the company achieved 100% insulin independence in 10 patients who underwent islet transplantation for type 1 diabetes. The FDA also granted Orphan Drug designation for tegoprubart in liver transplantation. However, the company faced a net loss of $39 million in this quarter, reflecting increased expenses and accounting for non-cash losses. Looking forward, Eledon plans to initiate several clinical trials and expects to progress towards Phase 3 development in kidney transplantation.
Read more →ELDNELEDON PHARMACEUTICALS, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (In thousands, except share and per share data) (Unaudited) For the Three Months Ended
Eledon Pharmaceuticals reported its Q1 2026 financial results, showcasing significant progress in its tegoprubart program. Notably, 100% insulin independence was achieved in 10 patients with type 1 diabetes after islet transplantation, and the FDA granted Orphan Drug designation to tegoprubart for liver transplantation. Despite a higher net loss compared to the previous year, the company expects several regulatory engagements and new clinical trials in the coming year to advance its innovative therapies.
Read more →ELDNBiotech Breakthrough
The article discusses a biotech company's commitment to transforming lives through innovative solutions and highlights its focus on patient stories and clinical trials. It emphasizes the importance of research and development in the biotech field. The company aims to make a significant impact on healthcare by advancing its pipeline and mechanisms of action.
Read more →ELDNWe fact-checked the hype behind the Eledon Pharmaceuticals Type 1 diabetes treatment
The article discusses the claims surrounding Eledon Pharmaceuticals' treatment for Type 1 diabetes. It highlights the company's focus on patient stories and clinical trials but lacks specific details about the treatment's efficacy or safety. The overall tone remains neutral, presenting information without strong endorsements or criticisms.
Read more →ELDNMAb-based immunosuppressant supports crucial diabetes cell transplants
The article discusses a monoclonal antibody (MAb)-based immunosuppressant that supports crucial diabetes cell transplants. This innovative treatment aims to improve transplant success rates and patient outcomes. The approach highlights the potential for transforming lives through effective organ transplantation. The advancements in immunosuppression are significant for diabetes patients requiring cell transplants.
Read more →ELDNBeating transplant challenges
The article discusses the challenges faced in organ transplantation and highlights various aspects of the organization involved in this field. It provides an overview of patient stories, clinical trials, and the scientific mechanisms behind organ transplants. Additionally, it touches on the organization's governance, financials, and investor relations.
Read more →ELDNTransplanting Islet Cells with Piotr Witkowski, MD, PhD
The article discusses the work of Dr. Piotr Witkowski in transplanting islet cells, highlighting the transformative impact on patients' lives. It provides an overview of the clinical trials and mechanisms involved in this innovative approach. The piece emphasizes the importance of ongoing research and patient stories in understanding the benefits of islet cell transplantation.
Read more →ELDNIn Vivo’s 2026 Rising Leaders
The article provides an overview of In Vivo's initiatives and focus areas, including patient stories, clinical trials, and their scientific mechanisms. It highlights the company's commitment to transforming lives through innovative approaches in healthcare. However, specific details about recent developments or achievements are lacking.
Read more →ELDN‘A cure on the horizon’: Are we finally close to ending type 1 diabetes?
The article discusses the promising developments in the treatment of type 1 diabetes, highlighting the potential for a cure. It emphasizes the importance of patient stories and ongoing clinical trials that may lead to significant breakthroughs. The tone is optimistic regarding future advancements in managing this condition.
Read more →ELDNDiabetes patients CURED of disease with groundbreaking new treatment, study shows
A recent study has revealed a groundbreaking treatment that has reportedly cured diabetes in patients. This innovative approach has shown promising results, with patients experiencing significant improvements in their health. The findings could potentially transform diabetes management and treatment options in the future.
Read more →ELDNEledon unveils new type 1 diabetes data
Eledon has announced new data related to type 1 diabetes, highlighting their ongoing commitment to transforming lives through innovative therapies. The company continues to focus on patient stories and clinical trials as part of their broader strategy. Further details on the mechanism of action and pipeline developments are also available.
Read more →ELDNTegoprubart enables insulin independence in type 1 diabetes islet transplant study
The article discusses a study on Tegoprubart, which has demonstrated the ability to enable insulin independence in patients undergoing islet transplants for type 1 diabetes. This advancement signifies a potential breakthrough in diabetes treatment, offering hope for improved patient outcomes. The findings could lead to significant changes in how type 1 diabetes is managed.
Read more →ELDNBreaking down the kidney transplant landscape on National Donor Day
The article discusses the kidney transplant landscape in relation to National Donor Day. It highlights the importance of organ donation and the impact it has on patients' lives. The content emphasizes the ongoing efforts in clinical trials and patient stories, showcasing the transformative nature of kidney transplants.
Read more →ELDNEledon Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Operating and Financial Results
Eledon Pharmaceuticals reported its fourth quarter and full year 2025 results, highlighting progress with tegoprubart, an anti-CD40L antibody. The drug has shown a favorable safety profile in clinical trials and received Orphan Drug designation for liver transplantation. The company anticipates multiple milestones, including advancing to Phase 3 trials in kidney transplantation and initiating new trials in islet and liver transplantation.
Read more →ELDNELEDON PHARMACEUTICALS, INC. CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (In thousands, except share and per share data) Year Ended
Eledon Pharmaceuticals reported its fourth quarter and full year 2025 operating results, highlighting significant advancements with its drug tegoprubart. The drug has received Orphan Drug designation from the FDA for liver transplantation and showed promising outcomes in type 1 diabetes patients. Despite a reported net loss of $45.6 million, Eledon expects to initiate multiple Phase 3 trials and continue exploring regulatory pathways for tegoprubart across various transplantation settings. The company remains focused on expanding its immunosuppressive therapies in clinical settings and addressing key patient needs.
Read more →ELDNEledon Announces Updated Data from Investigator-Initiated Islet Transplant Trial of Tegoprubart in Patients with Type 1 Diabetes at UChicago Medicine
Eledon Pharmaceuticals announced promising results from a trial of tegoprubart in Type 1 Diabetes patients undergoing islet transplantation. All 10 patients studied achieved insulin independence, with stable graft functions observed. Important safety outcomes indicated no graft rejection and minimal adverse effects associated with traditional immunosuppressants. The trial was conducted at UChicago Medicine and reflects potential advancement in diabetes treatment options.
Read more →ELDNEledon Pharmaceuticals Announces Orphan Drug Designation Granted to Tegoprubart for the Prevention of Allograft Rejection in Liver Transplantation
Eledon Pharmaceuticals announced that the FDA granted Orphan Drug designation to tegoprubart for preventing allograft rejection in liver transplantation. This designation is intended to encourage therapies for rare diseases with high unmet medical needs. Previous studies have shown that tegoprubart could improve graft survival while minimizing side effects commonly associated with traditional immunosuppressants. The company is optimistic about the potential of tegoprubart in this area and plans to initiate a clinical trial soon. Despite the positive developments, challenges related to clinical trial execution remain.
Read more →ELDNEledon Pharmaceuticals to Participate in Leerink Partners 2026 Global Healthcare Conference
Eledon Pharmaceuticals will participate in the Leerink Partners 2026 Global Healthcare Conference, featuring a fireside chat with CEO David-Alexandre C. Gros and President Steven Perrin. The event is scheduled for March 11, 2026. Eledon focuses on developing immune-modulating therapies, particularly its lead product, tegoprubart, targeting CD40L for various serious medical conditions.
Read more →ELDNArkansas woman participates in clinical trial to cure type one diabetes
An Arkansas woman has joined a clinical trial aimed at finding a cure for type 1 diabetes. This trial is part of ongoing research that seeks to transform the lives of patients suffering from this chronic condition. The initiative reflects advancements in medical science and offers hope for effective treatments in the future.
Read more →ELDN▲ +7.9%on this newsshared move
Tegoprubart is a Game Changer in Islet Cell Transplantation Surgery for T1D Patients
The article highlights the potential of Tegoprubart in revolutionizing islet cell transplantation for Type 1 Diabetes (T1D) patients. It discusses how this treatment could significantly improve patient outcomes and transform lives. The focus is on the positive impact of Tegoprubart, supported by patient stories and clinical trial results.
Read more →ELDNScrip Asks… What Does 2026 Hold for Biopharma? Part 4: R&D Innovation
The article discusses the future of biopharma, focusing on R&D innovation and its potential impact on patient care. It highlights the importance of clinical trials and the need for continuous advancements in treatment methodologies. The content emphasizes the ongoing efforts within the industry to enhance patient outcomes through innovative research.
Read more →ELDNTargeting Costimulatory Pathways in Kidney Transplant With Eliezer Katz, MD
The article discusses the focus on targeting costimulatory pathways in kidney transplant research led by Dr. Eliezer Katz. It highlights the importance of patient stories and clinical trials in advancing this area of study. The content emphasizes the organization's commitment to transforming lives through innovative approaches in organ transplantation.
Read more →ELDN2-Year Phase 1b Tegoprubart Preserves Kidney Function in Transplant Recipients, With Eliezer Katz, MD
The article discusses a 2-year Phase 1b study of Tegoprubart, which demonstrated its ability to preserve kidney function in transplant recipients. Led by Dr. Eliezer Katz, the trial's results indicate a potential breakthrough in post-transplant care, enhancing patient outcomes. The findings may pave the way for further research and development in this area.
Read more →ELDN▲ +11.2%on this newsshared move
Eledon Pharmaceuticals to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
Eledon Pharmaceuticals will participate in the Guggenheim Emerging Outlook: Biotech Summit 2026, with a fireside chat featuring Steven Perrin, Ph.D., on February 12, 2026. The company is known for its development of immune-modulating therapies, particularly its lead product, tegoprubart, which targets CD40 Ligand. This participation highlights Eledon's commitment to advancing its clinical stage biotechnology initiatives.
Read more →ELDNEledon Pharmaceuticals Presents Long-Term Phase 1b Data for Tegoprubart in Kidney Transplant Patients at the American Society of Transplant Surgeons Winter Symposium
Eledon Pharmaceuticals presented long-term Phase 1b data for tegoprubart at the American Society of Transplant Surgeons Winter Symposium. The study involved eight kidney transplant patients, showing no acute rejection or graft loss. Notably, the mean estimated glomerular filtration rate (eGFR) increased significantly over 24 months, indicating positive outcomes for the treatment.
Read more →ELDNFrom pig to patient: Pioneering transplants from pigs to humans could mark a turning point for organ replacement.
The article discusses the groundbreaking potential of transplants from pigs to humans, highlighting how this innovative approach could significantly change the landscape of organ replacement. It emphasizes the possibility of addressing the critical shortage of human organs, which could lead to life-saving treatments for patients in need. The advancements in this field are seen as a hopeful solution for many.
Read more →ELDNEledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2026 Outlook
Eledon Pharmaceuticals reported significant milestones in 2025, including positive Phase 2 trial results for tegoprubart in kidney transplantation. The company also noted preliminary success in treating type 1 diabetes post-islet transplantation. Eledon secured $57.5 million in financing, which will support its operations into mid-2027 as it prepares for Phase 3 development.
Read more →ELDNNew Immunosuppression Option May Ease Islet Cell Transplants
A new immunosuppression option is being explored to improve the outcomes of islet cell transplants. This development aims to enhance the success rates of these transplants, potentially transforming the lives of patients who rely on organ transplants for better health. The focus is on innovative approaches that could lead to more effective treatments.
Read more →ELDNGene-edited pig cardiac xenotransplantation as a bridge to allotransplantation in infants: Progress in a pig-to-baboon model
The article discusses advancements in gene-edited pig cardiac xenotransplantation, particularly its potential as a bridge to allotransplantation in infants. It highlights progress made in a pig-to-baboon model, showcasing the innovative approach and its implications for future transplant procedures. This research could significantly impact organ transplantation strategies.
Read more →ELDNTegoprubart vs Tacrolimus May Reduce Toxicities in Kidney Transplant Recipients
The article discusses the potential benefits of Tegoprubart compared to Tacrolimus in reducing toxicities for kidney transplant recipients. It highlights the importance of ongoing clinical trials and patient outcomes in evaluating the effectiveness of these treatments. The focus remains on improving patient care in the context of organ transplantation.
Read more →ELDNPromising Phase 2 Data for Tegoprubart in KT
The article discusses the promising Phase 2 data for Tegoprubart, a drug aimed at improving outcomes in kidney transplantation. It highlights the positive impact on patients and the potential for significant advancements in treatment. The data suggests that Tegoprubart could play a crucial role in transforming lives through enhanced organ transplant success.
Read more →ELDN▼ -6.1%on this news
Eledon Pharmaceuticals to Participate in the 37th Annual Piper Sandler Healthcare Conference
Eledon Pharmaceuticals announced its participation in the 37th Annual Piper Sandler Healthcare Conference, where CEO David-Alexandre C. Gros will engage in a fireside chat. The event is scheduled for December 4, 2025. Eledon is focused on developing immune-modulating therapies, particularly its lead product, tegoprubart, which targets CD40L for various serious conditions.
Read more →ELDNEledon Reports Preliminary Data from First Six Patients with Type 1 Diabetes Treated with Tegoprubart as the Core Immunosuppressant Following Islet Transplantation in Investigator-Initiated Trial at UChicago Medicine
Eledon Pharmaceuticals announced promising preliminary results from a clinical trial evaluating tegoprubart for preventing islet transplant rejection in type 1 diabetes patients. All six participants achieved insulin independence with significant improvements in glycemic control, showing HbA1c levels as low as 4.7%. The drug was well tolerated, with no serious adverse events reported. The ongoing trial at the University of Chicago Medicine is set to include twelve subjects as the study progresses, suggesting potential advancements in immunosuppression therapies for islet transplantation.
Read more →ELDNELEDON PHARMACEUTICALS, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (In thousands, except share and per share data) (Unaudited) For the Three Months Ended September 30, For the Nine Months
Eledon Pharmaceuticals has announced promising results from its Phase 2 BESTOW trial, which evaluated the immunosuppressive drug tegoprubart for preventing kidney transplant rejection. The trial demonstrated that tegoprubart significantly minimizes risks of common toxicities, prompting plans for Phase 3 development. In addition, the company secured $57.5 million in financing to enhance its transplantation initiatives. However, it reported a net loss of $17.5 million for Q3 2025, raising concerns about its ongoing financial health amidst substantial operating losses since its inception.
Read more →ELDNEledon Pharmaceuticals Announces Recent Business Highlights and Third Quarter 2025 Financial Results
Eledon Pharmaceuticals reported positive results from its Phase 2 BESTOW trial, indicating that tegoprubart has a favorable safety profile while significantly reducing common toxicities associated with tacrolimus. These results position tegoprubart for advancement into Phase 3 trials aimed at kidney transplant rejection prevention. Additionally, the company strengthened its financial position with a recent $57.5 million public offering to support further development in transplant medicine. However, the company reported a significant net loss this quarter compared to the same period last year, highlighting ongoing financial challenges.
Read more →ELDNBESTOW: Tegoprubart Showcases Safer Prevention of Kidney Transplant Rejection Over Tacrolimus
The article discusses Tegoprubart's effectiveness in preventing kidney transplant rejection, highlighting its safer profile compared to Tacrolimus. This advancement could significantly improve patient outcomes in organ transplantation. The focus is on the transformative potential of Tegoprubart in clinical settings.
Read more →ELDNTransplant and Trials: Redefining Care
The article discusses various aspects of organ transplantation and clinical trials, emphasizing patient stories and the scientific mechanisms behind the treatments. It highlights the importance of ongoing research and development in the field. The content also touches on corporate governance and investor relations, indicating a comprehensive approach to the subject.
Read more →ELDN▼ -11.3%on this news· ran to -24% by day 3shared move
Eledon Pharmaceuticals Announces Pricing of $50 Million Underwritten Public Offering of Common Stock and Pre-Funded Warrants
Eledon Pharmaceuticals has announced the pricing of a $50 million public offering, which includes 15,152,485 shares of common stock and pre-funded warrants. The offering is expected to close on or about November 13, 2025, pending customary closing conditions. Proceeds will be used for clinical development and general corporate purposes.
Read more →ELDN▼ -5.3%on this news· ran to -22% by day 3shared move
Eledon Pharmaceuticals Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants
Eledon Pharmaceuticals has announced a proposed underwritten public offering of its common stock and pre-funded warrants. The company aims to use the proceeds to further develop its clinical pipeline and for general corporate purposes. The offering is subject to market conditions, introducing uncertainty regarding its completion and terms. Leerink Partners and Cantor are the joint book-running managers for this offering.
Read more →ELDN▼ -49.8%on this newsshared move
x201c;targets,” “looks forward,” “could,” “may,” and similar expressions, constitute forward-looking statements within the meaning of the Private Securities Litigation Ref
Eledon Pharmaceuticals presented promising results from its Phase 2 BESTOW trial for tegoprubart, aimed at preventing kidney transplant rejection. The study showcased a favorable safety profile with reduced metabolic, neurologic, and cardiovascular toxicities compared to traditional tacrolimus. With an overall mean estimated glomerular filtration rate (eGFR) reported at 69 mL/min, the drug demonstrated potential in maintaining kidney function. Eledon plans to advance tegoprubart into Phase 3 development, subject to regulatory discussions.
Read more →ELDN▼ -49.8%on this newsshared move
Eledon Presents Phase 2 BESTOW Trial Results for Tegoprubart for the Prevention of Rejection in Kidney Transplantation at the American Society of Nephrology’s Kidney Week 2025 Annual Meeting
Eledon Pharmaceuticals presented positive results from its Phase 2 BESTOW trial for tegoprubart, aimed at preventing organ rejection in kidney transplants. The trial demonstrated a favorable safety profile, with reduced toxicities compared to tacrolimus. Eledon plans to advance tegoprubart into Phase 3 development, addressing a significant unmet need in transplant immunosuppression.
Read more →ELDNEledon Pharmaceuticals to Present at Guggenheim Second Annual Healthcare Innovation Conference
Eledon Pharmaceuticals announced that CEO David-Alexandre C. Gros will present at the Guggenheim Second Annual Healthcare Innovation Conference on November 12, 2025. The presentation will focus on the company's lead investigational product, tegoprubart, which targets CD40L for various serious conditions. A webcast of the event will be available for those who register in advance.
Read more →ELDNHow pig organs may soon save lives
The article discusses the promising potential of using pig organs for transplantation, highlighting advancements in xenotransplantation that could alleviate organ shortages. It emphasizes the life-saving impact this technology may have for patients in need of transplants. The narrative includes patient stories and clinical trials that showcase the effectiveness of this innovative approach.
Read more →ELDN▲ +20.7%on this news
Eledon Pharmaceuticals to Present Results from Phase 2 BESTOW Trial of Tegoprubart for the Prevention of Rejection in Kidney Transplantation at the American Society of Nephrology Kidney Week 2025 Annual Meeting
Eledon Pharmaceuticals announced an upcoming oral presentation at the American Society of Nephrology's Kidney Week 2025 Annual Meeting in Houston, TX. The presentation will focus on topline results from the Phase 2 BESTOW trial, which evaluates the efficacy and safety of tegoprubart for preventing rejection in kidney transplantation. Dr. Andrew Adams will lead the presentation on November 6, 2025, followed by a conference call on November 7 to discuss the results in greater detail. Eledon aims to advance its investigational product tegoprubart in the transplantation field.
Read more →ELDNGene-Edited Pig Kidneys Show Promise in Transplantation
The article discusses the promising results of gene-edited pig kidneys in transplantation, highlighting their potential to address the shortage of human organs. It emphasizes patient stories that showcase the transformative impact of this innovation. The research aims to improve the success rates of organ transplants through advanced genetic techniques.
Read more →ELDNEledon Pharmaceuticals to Present at the 18th Congress of the International Xenotransplantation Association
Eledon Pharmaceuticals will present at the 18th Congress of the International Xenotransplantation Association in Geneva. Dr. Steve Perrin, the company's President and Chief Scientific Officer, will lead a plenary session discussing the Anti-CD154 Pathway Blockade. This session will explore the implications of immunosuppression and immune monitoring in transplantation.
Read more →ELDNExtending the life of transplanted kidneys
The article discusses the efforts to extend the life of transplanted kidneys, highlighting the importance of organ transplantation in improving patient outcomes. It emphasizes the ongoing clinical trials and research aimed at enhancing the longevity and functionality of transplanted organs. The content is primarily focused on the organization's initiatives and patient stories related to organ transplantation.
Read more →ELDNXenotransplantation Moving Closer to Becoming a Clinical Reality
The article discusses the progress of xenotransplantation as it moves closer to clinical reality. It emphasizes the transformative potential of this technology in organ transplantation, showcasing patient stories that illustrate its impact. The advancements in clinical trials and research are also highlighted, indicating a positive trajectory for this innovative approach.
Read more →ELDNEledon Pharmaceuticals to Participate in Cantor Global Healthcare Conference 2025
Eledon Pharmaceuticals announced its participation in the Cantor Global Healthcare Conference, scheduled for September 5, 2025. CEO David-Alexandre C. Gros will lead a fireside chat at the event. The company is known for developing immune-modulating therapies, particularly its lead product, tegoprubart, aimed at treating serious health conditions.
Read more →ELDNXenotransplantation at the brink of breakthrough: A new era in organ transplantation
The article discusses the promising advancements in xenotransplantation, highlighting its potential to revolutionize organ transplantation. It emphasizes the transformative impact on patients' lives and the innovative mechanisms behind this approach. The focus on clinical trials and patient stories underscores the significance of these developments in the field.
Read more →ELDNEledon Pharmaceuticals Reports Second Quarter 2025 Operating and Financial Results
Eledon Pharmaceuticals reported its Q2 2025 financial results, highlighting a mean 12-month eGFR of approximately 68 mL/min/1.73 m2 for patients on tegoprubart. The company is set to release topline results from its Phase 2 BESTOW trial in kidney transplantation in November 2025. Despite a net loss of $11.2 million, Eledon maintains a strong cash position to fund operations through 2026.
Read more →ELDNELEDON PHARMACEUTICALS, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (In thousands, except share and per share data) (Unaudited) For the Three Months Ended June 30, For the Six Months Ended
Eledon Pharmaceuticals reported its second quarter 2025 financial and operating results, showcasing progress in clinical trials for its lead candidate, tegoprubart, which is aimed at preventing organ rejection. Positive data from a Phase 1b trial highlighted stable kidney function post-transplant for patients on the drug. The company anticipates reporting topline results from the Phase 2 BESTOW trial in November 2025. Despite reporting a net loss of $11.2 million for the quarter, Eledon maintains substantial cash reserves to fund its operations until late 2026.
Read more →ELDNEledon Pharmaceuticals’ ‘encouraging’ kidney transplant results
Eledon Pharmaceuticals has announced promising results from its clinical trials focused on kidney transplants. The data suggests that their treatment may significantly improve outcomes for transplant patients. This development aligns with the company's mission to enhance the quality of life for individuals undergoing organ transplants.
Read more →ELDN▲ +9.9%on this news
Eledon Presents Updated Data from Ongoing Phase 1b Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney Transplantation
Eledon Pharmaceuticals has presented updated data from its ongoing Phase 1b trial for tegoprubart, a drug aimed at preventing kidney transplant rejection. The trial indicates that patients on tegoprubart have shown a stable eGFR of approximately 68 mL/min/1.73 m² after a year. Preliminary biomarker data suggests that tegoprubart may improve long-term graft survival compared to existing treatments. While there were some rejection episodes, all were effectively managed, continuing to support tegoprubart's safety profile.
Read more →ELDN▲ +9.9%on this news
clinical trials, expected or future results of tegoprubart trials and its ability to prevent rejection in connection with kidney transplantation, as well as other statements containing the words “believes,”
Eledon Pharmaceuticals announced updated results from its ongoing Phase 1b clinical trial evaluating tegoprubart for preventing kidney transplant rejection. The results showed promising 12-month kidney function stabilization and suggested that tegoprubart may outperform traditional immunosuppressive therapies. Preliminary data indicated a potential for improved 5-year graft survival rates compared to existing treatments. Despite some reported rejection episodes, tegoprubart continues to demonstrate strong safety and tolerability metrics.
Read more →ELDNEledon Pharmaceuticals to Host a Conference Call to Discuss Updated Data from the Ongoing Phase 1b Trial of Tegoprubart in Kidney Transplantation Being Presented at the World Transplant Congress 2025
Eledon Pharmaceuticals will host a conference call on August 6, 2025, to discuss updated data from its Phase 1b trial of tegoprubart for preventing rejection in kidney transplant recipients. The data will be presented at the World Transplant Congress in San Francisco. Approximately 30 subjects are involved in the ongoing study.
Read more →ELDNExtending Transplant Life Through Targeted Innovation
The article highlights the innovative efforts of ELDN in extending the life of organ transplants. It emphasizes the importance of patient stories and clinical trials in showcasing the impact of their work. The focus on targeted innovation aims to transform lives, one organ at a time.
Read more →ELDNEledon Pharmaceuticals to Host R&D Day on July 9, 2025 in New York City
Eledon Pharmaceuticals has announced that it will host an R&D Day in New York City on July 9, 2025. The event will showcase Eledon’s lead candidate, tegoprubart, and its development in organ transplantation. Notable experts in the field will participate, discussing critical topics, including ongoing clinical trials and unmet needs in solid organ transplantation. The program will include a live Q&A session with Eledon’s management and key opinion leaders.
Read more →ELDNEledon leading a paradigm shift in immunosuppression therapy in organ transplantation
Eledon is leading a significant shift in immunosuppression therapy for organ transplantation. The company focuses on innovative solutions that aim to improve patient outcomes and transform lives. Their commitment to advancing clinical trials and sharing patient stories underscores the impact of their therapies in the field.
Read more →ELDNEledon Pharmaceuticals Reports First Quarter 2025 Operating and Financial Results
Eledon Pharmaceuticals reported its Q1 2025 financial results and business updates, highlighting progress in its Phase 2 BESTOW trial for kidney transplantation, with topline results expected in Q4 2025. The company announced the successful use of tegoprubart in a transplant of a genetically modified pig kidney into a human. Eledon's financial health remains robust, with cash and equivalents of $124.9 million. However, the company recorded a net loss of $6.5 million in the quarter, signifying increased spending on research and development.
Read more →ELDNCHLA Team Is First in World to Investigate Cardiac Xenotransplant as a ‘Bridge’ for Babies
The CHLA team has become the first in the world to explore cardiac xenotransplantation as a potential bridge therapy for infants with severe heart conditions. This groundbreaking approach aims to provide a viable solution for young patients in need of heart transplants, addressing a critical gap in pediatric care. The initiative highlights the potential of xenotransplantation to save lives and improve outcomes for vulnerable populations.
Read more →ELDNDavid-Alexandre Gros, MD, on the Work to Bring Porcine Kidney Transplant to the Clinic
The article discusses the efforts led by David-Alexandre Gros, MD, to advance porcine kidney transplants into clinical practice. It highlights the potential of xenotransplantation to address organ shortages. However, specific details about clinical trials or outcomes are not provided, leaving the discussion at a conceptual level.
Read more →ELDNGene Editing, Next-Gen Antibodies Key to Unlocking Animal-to-Human Transplants
The article discusses the potential of gene editing and next-generation antibodies in facilitating animal-to-human organ transplants. It highlights the transformative impact these technologies could have on organ donation and transplantation. However, specific details on current advancements or challenges are not provided.
Read more →ELDNEledon Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Operating and Financial Results
Eledon Pharmaceuticals reported its financial and operational results for Q4 and the full year of 2024. The company highlighted progress in using its drug, tegoprubart, in significant transplant procedures, including a genetically modified pig kidney transplant and initial positive outcomes in type 1 diabetes trials. Despite a net loss of $44.6 million in Q4, the company is optimistic, signaling a strong cash position that will support operations into 2026. Key upcoming milestones include topline results from the Phase 2 BESTOW trial expected in late 2025.
Read more →ELDNDavid-Alexandre Gros, MD, on Using Tegoprubart to Support Genetically Modified Xenotransplant
David-Alexandre Gros, MD, discusses the application of Tegoprubart in supporting genetically modified xenotransplantation. The article highlights the potential benefits and mechanisms of action of Tegoprubart in this innovative area of research. However, specific outcomes or data related to the use of Tegoprubart in clinical settings are not detailed.
Read more →ELDNDavid-Alexandre Gros, MD, on Addressing Unmet Needs in End Stage Kidney Disease With Genetically Modified Porcine Kidney Transplant
The article discusses the efforts of David-Alexandre Gros, MD, in addressing unmet needs in end-stage kidney disease through genetically modified porcine kidney transplants. The focus is on transforming lives by exploring innovative organ transplant solutions. However, specific details about clinical trials or outcomes are not provided.
Read more →ELDNEledon Pharmaceuticals to Participate in Leerink Partners Global Healthcare Conference
Eledon Pharmaceuticals, Inc. has announced that its Chief Scientific Officer and President, Steve Perrin, will participate in the upcoming Leerink Partners Global Healthcare Conference. This event is scheduled for March 11, 2025, at 2:20 p.m. ET. During the conference, Eledon will discuss their leading investigational product, tegoprubart, an anti-CD40L antibody targeting immune modulation. The company continues to pursue innovative therapies for severe medical conditions such as kidney transplantation and ALS.
Read more →ELDNScrip Asks… What Does 2025 Hold For Biopharma? Part 6: Therapeutic Area Advances
The article discusses the future of biopharma, particularly focusing on therapeutic area advancements expected by 2025. It highlights various aspects of the industry, including patient stories, clinical trials, and the importance of innovative therapies. The content is structured to provide insights into the evolving landscape of biopharmaceuticals.
Read more →ELDNCD40L Blocker Tegoprubart Playing Key Role in Xenotransplantation
The article discusses the role of Tegoprubart, a CD40L blocker, in xenotransplantation. It highlights the potential of this therapy to transform organ transplantation processes. However, the article lacks specific details about clinical outcomes or ongoing trials related to Tegoprubart.
Read more →ELDNIslet Cell Replacement and Regeneration for Type 1 Diabetes: Current Developments and Future Prospects
The article discusses current developments and future prospects in islet cell replacement and regeneration for Type 1 Diabetes. It highlights the importance of clinical trials and patient stories, while also providing insights into the scientific mechanisms and pipeline of related therapies. However, specific advancements or challenges are not detailed.
Read more →ELDNA Second Person Has Received a Pig Kidney Transplant
A second person has successfully received a pig kidney transplant, marking a significant advancement in xenotransplantation. This innovative procedure aims to address the critical shortage of human organs available for transplantation. The success of this transplant could pave the way for broader applications in organ replacement therapies.
Read more →ELDNFor Second Kidney Xenotransplant Patient Discharged, Immunosuppression Is Key
The article discusses the successful discharge of a second patient who received a kidney xenotransplant. It emphasizes the importance of immunosuppression in ensuring the patient's recovery. This achievement marks a significant milestone in the field of organ transplantation, showcasing advancements in medical technology.
Read more →ELDNeGenesis announces 2nd pig kidney procedure success, as xenotransplantation field moves forward
eGenesis has successfully completed its second pig kidney transplant procedure, marking a significant advancement in the field of xenotransplantation. This achievement highlights the potential of using genetically modified pig organs to address the shortage of human organ donors. The ongoing progress in this area may lead to transformative solutions for patients in need of organ transplants.
Read more →ELDNSecond Xenotransplant with Gene-Edited Pig Kidney Performed at Mass General
Mass General has successfully performed its second xenotransplant using a gene-edited pig kidney. This groundbreaking procedure demonstrates significant advancements in organ transplantation, potentially improving patient outcomes. The use of genetically modified organs could address the ongoing shortage of human organ donors.
Read more →ELDNeGenesis completa con éxito su segundo xenotrasplante de riñón de cerdo en humanos
eGenesis has successfully completed its second xenotransplant of a pig kidney into a human patient. This significant milestone showcases the company's progress in xenotransplantation, which could address the organ shortage crisis. The procedure marks a critical step in developing alternative organ sources for transplantation.
Read more →ELDNEledon touts tegoprubart used in pig kidney transplant
Eledon has announced the use of tegoprubart in pig kidney transplants, emphasizing its potential to transform organ transplantation. The company is focused on improving patient outcomes and sharing impactful stories from their clinical trials. This development marks a significant step forward in the field of organ transplantation.
Read more →ELDNEledon Pharmaceuticals Announces Use of Tegoprubart as Key Component of Immunosuppression Regimen in its Second Transplant of a Genetically Modified Pig Kidney into a Human
Eledon Pharmaceuticals announced that its investigational therapy tegoprubart was used in a kidney transplant from a genetically modified pig to a human at Massachusetts General Hospital. This initiative, conducted in collaboration with eGenesis, represents a significant advancement in xenotransplantation. The patient has been discharged and is off dialysis for the first time in over two years. Eledon plans to further investigate tegoprubart’s effectiveness in preventing organ rejection in ongoing trials.
Read more →ELDNEledon Pharmaceuticals to Participate in Guggenheim Securities SMID Cap Biotech Conference
Eledon Pharmaceuticals announced its participation in the Guggenheim Securities SMID Cap Biotech Conference, scheduled for February 5, 2025. CEO David-Alexandre C. Gros and CSO Steve Perrin will lead a fireside chat, providing insights into the company's work and therapies. Eledon is known for developing immune-modulating therapies such as tegoprubart, an anti-CD40L antibody. The event underscores the company's commitment to advancing treatment options in areas with significant unmet medical needs.
Read more →ELDNEledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2025 Outlook
Eledon Pharmaceuticals achieved significant business milestones in 2024, including completing enrollment in the Phase 2 BESTOW trial for tegoprubart four months ahead of schedule. The company presented data supporting the safety and tolerability of tegoprubart in kidney transplantation and reported encouraging initial results for type 1 diabetes patients. They completed financings totaling $135 million to support operations until 2026. Eledon is positioned for important milestones in 2025, including reporting topline results from ongoing trials.
Read more →ELDNTargeting the CD40L Pathway to Improve Immunosuppression Therapy & Help Organ Transplants Last Longer
The article discusses advancements in targeting the CD40L pathway to enhance immunosuppression therapy, which could lead to longer-lasting organ transplants. This innovative approach aims to improve patient outcomes and transform lives through better organ transplant management. The focus on this pathway highlights the potential for significant advancements in transplant medicine.
Read more →ELDNEledon Works Toward Potential T1D Treatment
Eledon is making strides towards developing a treatment for Type 1 Diabetes (T1D). The company emphasizes its commitment to patient care and innovative solutions. Their ongoing clinical trials and research efforts are aimed at improving the lives of those affected by T1D.
Read more →ELDNMarlaina Goedel’s Story
Marlaina Goedel, diagnosed with type 1 diabetes at five, faced numerous challenges, including severe health risks and emotional strain on her family. After a life-changing islet transplant at age 30, she has found hope and is now pursuing a career in horse therapy. Marlaina is dedicated to sharing her story and inspiring others affected by diabetes.
Read more →ELDNDaniel Gilada’s Story
Daniel Gilada, diagnosed with type 1 diabetes at 18, has navigated significant health challenges while balancing his career as a cardiologist and family life. After years of fluctuating glucose levels and emotional struggles, he chose to participate in an islet transplant clinical trial. He emphasizes the importance of seeking help and support for those facing similar challenges.
Read more →ELDNHopkins alum leads Eledon Pharmaceuticals in breakthrough diabetes tegoprubart treatment
Eledon Pharmaceuticals, led by a Hopkins alum, is making strides in diabetes treatment with its innovative drug, tegoprubart. This breakthrough therapy aims to improve patient outcomes significantly. The company's focus on transforming lives underscores its commitment to advancing healthcare solutions.
Read more →ELDNExperimental diabetes treatment helps Chicago woman go off insulin
An experimental diabetes treatment has enabled a Chicago woman to discontinue her insulin use, showcasing the potential benefits of the new therapy. This advancement highlights the ongoing efforts in diabetes management and the transformative impact of innovative treatments on patients' lives. The treatment's success could pave the way for further clinical trials and research in diabetes care.
Read more →ELDNELEDON PHARMACEUTICALS, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) (In thousands, except share and per share data) (Unaudited) For the Three Months Ended September 30, For the Ni
Eledon Pharmaceuticals reported strong third quarter results, completing enrollment for its Phase 2 BESTOW trial ahead of schedule. The company announced positive data from an investigator-led trial for type 1 diabetes, where patients treated with tegoprubart achieved insulin independence. Additionally, Eledon secured $85 million in an oversubscribed stock offering, extending its financial runway until the end of 2026. However, the reported net income increase was largely attributed to non-cash gains, raising concerns about underlying operational profitability.
Read more →ELDNEledon Pharmaceuticals Announces Recent Business Highlights and Third Quarter 2024 Financial Results
Eledon Pharmaceuticals has completed enrollment in its Phase 2 BESTOW trial of the immunosuppressant drug tegoprubart, four months earlier than planned. Initial positive data from a related trial on type 1 diabetes patients treated with tegoprubart has also been reported, indicating potential insulin independence in subjects. Additionally, Eledon successfully raised $85 million through an oversubscribed underwritten offering, which is expected to extend the company's cash runway into 2026. The topline results from the BESTOW trial are anticipated in the fourth quarter of 2025.
Read more →ELDNEledon Pharmaceuticals to Participate in Guggenheim Securities Inaugural Healthcare Innovation Conference
Eledon Pharmaceuticals will participate in the Guggenheim Securities Inaugural Healthcare Innovation Conference on November 13, 2024. CEO David-Alexandre C. Gros, M.D. will engage in a fireside chat during the event. Eledon is a clinical-stage biotechnology firm focusing on immune-modulating therapies, with its lead product being tegoprubart, an anti-CD40L antibody. The company aims to address critical health issues such as kidney allograft transplantation and amyotrophic lateral sclerosis (ALS).
Read more →ELDN▲ +16.7%on this news· ran to +35% by day 3
(212) 253 8881 jurban@berrypr.com Source: Eledon Pharmaceuticals
Eledon Pharmaceuticals has announced an underwritten offering of common stock and pre-funded warrants, aiming to raise approximately $85 million. This offering includes the sale of 18,356,173 shares at $3.65 each and 4,931,507 pre-funded warrants at $3.649 each. The use of proceeds is intended for advancing its pipeline and fulfilling general corporate purposes. Participation from multiple investors highlights confidence in the company's future, although the offering's completion is subject to customary closing conditions.
Read more →ELDN▲ +6.5%on this news· ran to +57% by day 3shared move
Eledon Pharmaceuticals Announces Positive Initial Data from Subjects with Type 1 Diabetes Treated with Tegoprubart as Part of an Immunosuppression Regimen Following Islet Transplantation in Investigator-Initiated Trial at UChicago Medicine
Eledon Pharmaceuticals announced encouraging results from an investigator-initiated trial in which subjects with Type 1 Diabetes receiving tegoprubart as part of their immunosuppressive regimen achieved significant outcomes. The first two participants maintained insulin independence, and the third subject is on track for similar results. Notably, islet engraftment rates were three to five times higher than those on standard tacrolimus-based therapy, indicating a potential improvement in transplant outcomes with tegoprubart. These findings highlight the investigational therapy's promising role in enhancing islet transplantation success.
Read more →ELDN▲ +6.5%on this news· ran to +57% by day 3shared move
Eledon Pharmaceuticals Announces Pricing of $85 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
Eledon Pharmaceuticals has announced the pricing of its underwritten offering of common stock and pre-funded warrants, expecting to raise approximately $85 million. The offering includes 18,356,173 shares priced at $3.65 each and pre-funded warrants for 4,931,507 shares. The anticipated use of the proceeds is to enhance their pipeline and for general corporate purposes. The offering is scheduled to close on or around October 30, 2024, subject to customary conditions.
Read more →ELDN▲ +6.5%on this news· ran to +57% by day 3shared move
Forward-Looking Statements This press release contains forward-looking statements that involve substantial risks and uncertainties. Any statements about the company's future expectations, plans and prospects, including s
Eledon Pharmaceuticals reported promising results from an investigator-initiated trial at UChicago Medicine involving their investigational drug, tegoprubart, for preventing islet transplant rejection in type 1 diabetes patients. The initial data indicate that two out of three subjects achieved insulin independence, while the third subject is on track achieving similar outcomes. Notably, islet engraftment in the treated group was three to five times higher than that seen with standard tacrolimus-based immunosuppression. The treatment was well-tolerated, with no unexpected adverse events noted.
Read more →ELDNNew therapy after islet cell transplant shows promise for people with Type 1 diabetes
A new therapy has emerged that shows promise for individuals with Type 1 diabetes following islet cell transplants. This innovative approach aims to enhance patient outcomes and transform lives by addressing the challenges faced post-transplant. The therapy's mechanism of action and its implications for future treatments are currently under exploration.
Read more →ELDNI’m one of the first Americans to be cured of type 1 diabetes thanks to a breakthrough therapy
A recent article highlights the success of a breakthrough therapy that has cured type 1 diabetes in some patients. This innovative treatment is transforming lives and represents a significant advancement in diabetes care. The therapy has garnered attention for its potential to change the future of diabetes management.
Read more →ELDNNew treatment for type 1 diabetics gives hope to University of Chicago patients
A new treatment for type 1 diabetes has emerged, providing hope for patients at the University of Chicago. The innovative approach aims to transform the lives of those living with this chronic condition. With promising results, the treatment could significantly enhance the quality of life for many individuals affected by diabetes.
Read more →ELDNA Better Drug May Make Transplants More Successful
The article discusses advancements in drug development that may enhance the success of organ transplants. It emphasizes the positive impact on patients' lives and highlights the innovative mechanisms of action in the pipeline. The focus on patient stories underscores the importance of these developments in transforming lives.
Read more →ELDNTwo type 1 diabetes patients are insulin-free after Eledon’s immunosuppressant and an islet transplant
Eledon has reported that two patients with type 1 diabetes have achieved insulin independence following treatment with its immunosuppressant and islet transplant. This breakthrough highlights the potential of Eledon's therapies to significantly improve the lives of individuals with diabetes. The success of these cases may pave the way for further advancements in diabetes treatment.
Read more →ELDNEledon Pharmaceuticals Announces Positive Initial Data From Subjects With Type 1 Diabetes Treated With Tegoprubart as Part of an Immunosuppression Regimen Following Islet Transplantation
Eledon Pharmaceuticals has announced promising initial data regarding Tegoprubart, which is being tested in subjects with Type 1 diabetes as part of an immunosuppression regimen following islet transplantation. The results indicate positive outcomes, suggesting the drug's potential effectiveness in this patient population. This development could significantly impact treatment strategies for Type 1 diabetes.
Read more →ELDNUChicago researchers may have found ‘functional cure’ for Type 1 diabetes
Researchers from the University of Chicago have potentially identified a 'functional cure' for Type 1 diabetes. This breakthrough could transform the management of the disease, offering new hope to patients. The study highlights innovative approaches in diabetes treatment, showcasing the significant impact of ongoing medical research.
Read more →ELDNEledon drug helps transplants ‘cure’ type 1 diabetes
Eledon has developed a drug that demonstrates potential in curing type 1 diabetes, particularly in the context of organ transplants. The drug's mechanism of action and clinical trials suggest a transformative impact on patients' lives. Positive patient stories further emphasize the drug's effectiveness and potential benefits.
Read more →ELDNEledon unveils first evidence of insulin independence in tegoprubart-treated islet transplants
Eledon has announced the first evidence of insulin independence in patients receiving islet transplants treated with tegoprubart. This breakthrough suggests that tegoprubart may enhance the effectiveness of islet transplants, offering new hope for patients with diabetes. The findings could significantly impact future treatment protocols and patient outcomes.
Read more →ELDNEledon Pharmaceuticals to Present at the Cantor Global Healthcare Conference
Eledon Pharmaceuticals, Inc. has announced that CEO David-Alexandre C. Gros will participate in a fireside chat at the Cantor Global Healthcare Conference on September 18, 2024. The company is known for developing immune-modulating therapies, particularly its lead product, tegoprubart. This antibody targets CD40 Ligand, suggesting potential broad therapeutic applications. A webcast of the chat will be available following the live session on the company's website.
Read more →ELDN▼ -5.8%on this news
Eledon Announces Completion of Enrollment in Phase 2 BESTOW Clinical Trial Assessing Tegoprubart for Prevention of Organ Rejection in Kidney Transplant Patients
Eledon Pharmaceuticals announced the swift completion of participant enrollment in its Phase 2 BESTOW clinical trial, which evaluates the efficacy of tegoprubart in preventing organ rejection in kidney transplant patients. Achieving the target enrollment of 120 participants four months ahead of schedule underscores the strong interest in this new immunosuppressive therapy. The trial's primary goal is to assess graft function compared to the standard treatment, tacrolimus. Eledon anticipates sharing top-line results from the study by the fourth quarter of 2025, reflecting confidence in the innovative potential of tegoprubart.
Read more →ELDNSwitching Off Autoimmunity
The article provides a broad overview of ELDN's initiatives and resources, focusing on patient stories, clinical trials, and corporate governance. It highlights the company's commitment to transforming lives through innovative approaches. However, it lacks specific details about recent developments or breakthroughs in their pipeline.
Read more →ELDNWhere Are the Cell Therapies for Type 1 Diabetes?
The article discusses the current landscape of cell therapies for Type 1 Diabetes, highlighting various aspects such as patient stories, clinical trials, and the scientific mechanisms behind these therapies. It provides an overview of the ongoing research and developments in this field, though it lacks specific updates or breakthroughs. The content is structured to inform readers about the potential of cell therapies in transforming diabetes treatment.
Read more →ELDNInvestor Contact: Stephen Jasper Gilmartin Group (858) 525 2047 stephen@gilmartinir.com Media Contact: Jenna Urban Berry & Company Public Relations (212) 253 8881 jurban@berrypr.com Source: Eledon Pharmaceuticals
Eledon Pharmaceuticals has reported preliminary operating results for Q2 2024, highlighting that 80 participants have been enrolled in the ongoing Phase 2 BESTOW trial evaluating tegoprubart for kidney transplantation. The company has successfully completed an oversubscribed private placement, securing $50 million in funding expected to last until December 2025. Notably, preliminary data from the Phase 1b trial indicate that tegoprubart is generally safe and well-tolerated. However, Eledon plans to restate some previously issued financial documents due to necessary accounting adjustments.
Read more →ELDNEledon Pharmaceuticals Reports Preliminary Second Quarter 2024 Operating Results
Eledon Pharmaceuticals has reported its preliminary operating results for the second quarter of 2024, highlighting key developments in its clinical trials and financial health. The company has enrolled 80 participants in its Phase 2 BESTOW trial for tegoprubart, which aims to prevent organ rejection in kidney transplant patients. Recent data showcased the drug's safety profile, supporting its potential as an alternative to the current standard of care. However, the company will delay the filing of its quarterly report due to necessary financial restatements.
Read more →ELDNSean Elliot’s Story
The article highlights the commitment to advancing next-generation therapies aimed at improving patient outcomes. It emphasizes the importance of patient stories and clinical trials in the development process. Additionally, it provides insights into the company's leadership and governance structure.
Read more →ELDNEledon Provides Enrollment Update for Phase 2 BESTOW Trial Assessing Tegoprubart for the Prevention of Organ Rejection
Eledon Pharmaceuticals has provided an update on its Phase 2 BESTOW trial for tegoprubart, having successfully enrolled the 80th participant. The company reported that two-thirds of the anticipated 120 participants have been recruited across multiple regions, showcasing strong interest from clinical teams and participants. The trial aims to explore the efficacy of tegoprubart in preventing organ rejection in kidney transplantation, with an expected completion date for recruitment by the end of the year.
Read more →ELDNEledon to Participate in the Leerink Partners Therapeutics Forum: I&I and Metabolism
Eledon Pharmaceuticals has announced its participation in the upcoming Leerink Partners Therapeutics Forum, scheduled for July 9, 2024, in Boston, MA. During the forum, the company will host one-on-one meetings to discuss its ongoing development of immune-modulating therapies. Eledon's lead product, tegoprubart, is an anti-CD40L antibody that targets key pathways in immune response, positioning the company favorably in the biotechnology space.
Read more →ELDNThis Drug Enables Breakthrough Organ Transplants
The article discusses a new drug that facilitates breakthrough organ transplants, showcasing its potential to transform patients' lives. It highlights patient stories and the positive outcomes observed in clinical trials. The drug's mechanism of action and its place in the pipeline are also briefly mentioned, indicating a significant advancement in transplant technology.
Read more →ELDN▼ -5.2%on this news· ran to +21% by day 3shared move
First Living Patient Received Pig Kidney Transplant
A significant medical milestone has been achieved with the first living patient receiving a pig kidney transplant. This groundbreaking procedure represents a potential solution to the ongoing organ shortage crisis. The success of this transplant could pave the way for future xenotransplantation advancements, offering hope to many patients in need of organ transplants.
Read more →ELDNEledon Pharmaceuticals Reports First Quarter 2024 Operating and Financial Results
Eledon Pharmaceuticals reported its first quarter 2024 results, highlighting notable advancements, including the initiation of clinical trials with their drug tegoprubart aimed at preventing transplant rejection in patients. The company secured a $50 million private placement and has begun using tegoprubart in a unique immunosuppressive regimen following a kidney xenotransplant. Eledon plans to report further trial data and complete enrollment for ongoing studies later in 2024.
Read more →ELDNEledon Pharmaceuticals to Present Updated Data from Ongoing Phase 1b Trial of Tegoprubart in Patients Undergoing Kidney Transplantation at the American Transplant Congress
Eledon Pharmaceuticals has announced that it will present updated data from its ongoing Phase 1b trial of tegoprubart at the American Transplant Congress in Philadelphia from June 1-5, 2024. The poster will cover biomarkers of inflammation and eGFR in the context of preventing rejection in kidney transplant patients. Eledon will also sponsor a satellite symposium featuring several notable experts in the field. The company’s research focuses on immune-modulating therapies for critical conditions.
Read more →ELDN▼ -7.4%on this newsshared move
signaling in both adaptive and innate immune cell activation and function positions it as an attractive target for non-lymphocyte depleting, immunomodulatory therapeutic intervention. The Company is building upon a deep
Eledon Pharmaceuticals announced a successful oversubscribed private placement, raising approximately $50 million from institutional and accredited investors. The company plans to use the proceeds to fund pre-commercial activities and the clinical development of its lead asset, tegoprubart, an anti-CD40L antibody. The financing was facilitated by BVF Partners LP and included participation from various investors, while leading agents included Leerink Partners, LifeSci Capital, and Noble Capital Markets. The closing of the financing is anticipated for the week of May 6, 2024, subject to customary conditions.
Read more →ELDN▼ -7.4%on this newsshared move
Eledon Announces Clinical Progress with Tegoprubart in the Prevention of Transplant Rejection
Eledon Pharmaceuticals has reported significant progress regarding tegoprubart, a novel anti-CD40L antibody, in clinical trials aimed at preventing transplant rejection. The first participant has been dosed in an investigator-led trial for preventing islet cell transplant rejection in type 1 diabetes patients. Additionally, updated data from an ongoing Phase 1b trial has shown that tegoprubart successfully prevents kidney transplant rejection while being generally safe and well-tolerated. The company plans to present further findings at the upcoming American Transplant Congress in June 2024.
Read more →ELDN▼ -7.4%on this newsshared move
Eledon Pharmaceuticals Announces Oversubscribed $50 Million Private Placement
Eledon Pharmaceuticals has announced an oversubscribed private placement that will generate approximately $50 million in gross proceeds. The funding will be utilized for pre-commercial activities and to advance the clinical development of their lead product, tegoprubart, which targets immune modulation. Closing of the financing is expected to occur during the week of May 6, 2024. The securities sold will not be offered to the public and a registration statement will be filed with the SEC for resale.
Read more →ELDNThe Making of a Medical Milestone
The article discusses the transformative impact of ELDN's medical innovations on patients' lives. It highlights their focus on clinical trials and the importance of patient stories in showcasing the effectiveness of their treatments. The company aims to advance medical science through its dedicated research and development efforts.
Read more →ELDNWith a Rise in Animal-Human Organ Transplants, a Drugmaker Aims for a New Standard of Care
The article discusses the rise in animal-human organ transplants and how a drugmaker is positioning itself to set a new standard of care in this emerging field. It highlights the transformative potential of these transplants for patients in need of organ replacements. The company aims to leverage advancements in this area to improve patient outcomes significantly.
Read more →ELDNCould Eledon’s Anti-CD40L Change Transplant Medicine?
The article discusses Eledon's potential impact on transplant medicine through its Anti-CD40L therapy. It highlights the company's focus on transforming organ transplantation and improving patient outcomes. However, specific details about clinical trials or results are not provided, leaving the overall sentiment neutral.
Read more →ELDNKidney Xenotransplantation Project
The article discusses a kidney xenotransplantation project, emphasizing its potential to transform lives by providing organ transplants. It outlines various aspects of the initiative, including patient stories, clinical trials, and the scientific mechanisms involved. However, specific details regarding the project's progress or outcomes are not provided.
Read more →ELDNHe Got a Pig Kidney Transplant. Now Doctors Need to Keep It Working
The article discusses the recent kidney transplant of a patient using a pig kidney. Doctors are now focused on ensuring the transplanted organ functions effectively. This case highlights advancements in xenotransplantation and the ongoing challenges in organ transplantation.
Read more →ELDNEledon’s Antibody Aids First Gene-Edited, Pig-to-Human Kidney Transplant
Eledon has achieved a milestone by utilizing its antibody in the first successful pig-to-human kidney transplant, aided by gene-editing techniques. This pioneering procedure is expected to transform organ transplantation, offering new hope for patients in need of kidney transplants. The advancement highlights the potential of combining biotechnology with organ donation.
Read more →ELDNAdvances in Immunosuppression Research May Bring Transplant Patients Closer to “One Organ for Life”
Recent advancements in immunosuppression research are paving the way for transplant patients to potentially receive a single organ for life. This innovative approach aims to enhance the longevity and effectiveness of organ transplants, significantly improving patient outcomes. The focus on patient stories underscores the transformative impact of these developments in the field.
Read more →ELDNEledon Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Operating and Financial Results
Eledon Pharmaceuticals has reported its fourth quarter and full year 2023 results, highlighting significant progress in its clinical trials for tegoprubart, aimed at preventing kidney transplant rejection. The company has enrolled participants in both a Phase 2 trial, BESTOW, and a Phase 1b trial, showing promising results in safety and efficacy. Notably, tegoprubart was utilized in a groundbreaking pig-to-human kidney transplant procedure. Although Eledon achieved success in clinical enrollment, it continues to face financial losses as it invests in further research and development.
Read more →ELDNEledon Pharmaceuticals Announces 12th Participant Enrolled in Phase 2 BESTOW Trial Evaluating Tegoprubart for the Prevention of Organ Rejection
Eledon Pharmaceuticals has announced the enrollment of the 12th participant in its Phase 2 BESTOW trial, which evaluates tegoprubart against tacrolimus for preventing organ rejection in kidney transplants. The company’s CEO noted the rapid enrollment as an indication of strong demand for improved immunosuppressive solutions. Tegoprubart aims to address significant issues associated with current therapies, such as the toxicities linked to calcineurin inhibitors. The trial's success could represent a notable advancement in post-transplant care for kidney recipients.
Read more →ELDN▲ +11.2%on this news· ran to +25% by day 3shared move
Eledon Pharmaceuticals Announces Use of Tegoprubart in First-ever Transplant of Genetically Modified Kidney from a Pig to a Human
Eledon Pharmaceuticals announced the successful use of tegoprubart during the first kidney transplant from a genetically modified pig to a human, performed at Massachusetts General Hospital. The investigational drug has shown promising results in preventing organ rejection and maintaining robust kidney function post-transplantation. This landmark procedure may pave the way for new solutions to the global shortage of available organs. Eledon is actively conducting clinical studies to further evaluate tegoprubart's potential as an immunosuppressive treatment in transplantation.
Read more →ELDNEledon Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Eledon Pharmaceuticals announced the grant of restricted stock units (RSUs) and stock options to a new employee as an inducement in accordance with Nasdaq Listing Rule 5635(c)(4). The grant includes 42,500 RSUs and stock options for 90,000 common shares at an exercise price of $1.77. The RSUs fully vest after one year, while the stock options have a four-year vesting period. Eledon is focused on developing therapies targeting immune modulation for serious conditions.
Read more →ELDNEledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2024 Outlook
Eledon Pharmaceuticals has highlighted significant milestones achieved in 2023 and outlined its outlook for 2024. The company reported successful results from its Phase 1b trial of tegoprubart, demonstrating its efficacy in preventing kidney transplant rejection. Eledon has initiated its Phase 2 BESTOW trial and participated in notable xenotransplant procedures. With up to $185 million in financing secured, the company aims to advance its clinical trials and further explore the potential of tegoprubart in transplantation therapies.
Read more →ELDN▼ -6.7%on this newsshared move
Eledon Pharmaceuticals to Present at Noble Capital Markets' Emerging Growth Equity Conference
Eledon Pharmaceuticals announced that its CEO, Dr. David-Alexandre C. Gros, will present at the Noble Capital Markets' Emerging Growth Equity Conference on December 4, 2023. Dr. Gros is also set to take part in a panel discussion on organ transplantation during the conference, which will be held in Boca Raton, Florida. This opportunity allows Eledon to outline its clinical stage developments and engage with stakeholders in the biotechnology sector.
Read more →ELDNEledon Pharmaceuticals Reports Third Quarter 2023 Operating and Financial Results
Eledon Pharmaceuticals announced their third quarter 2023 operating and financial results, highlighting significant progress in their clinical trials, particularly with tegoprubart for kidney transplant patients. The Phase 1b trial results showed that tegoprubart effectively prevented transplant rejection and improved organ function. Additionally, the company has commenced the Phase 2 BESTOW trial and reported a net loss for the quarter, alongside increased R&D costs. Eledon's leadership team has also seen new appointments, underscoring their commitment to advancing their pipeline.
Read more →ELDNEledon Pharmaceuticals to Present at Jefferies London Healthcare Conference
Eledon Pharmaceuticals is scheduled to present at the Jefferies London Healthcare Conference on November 16, 2023. CEO David-Alexandre C. Gros will provide an overview of the company and its lead investigational product, tegoprubart. This anti-CD40L antibody targets the CD40 Ligand pathway, significant for immunomodulatory therapeutic interventions. The company specializes in therapies for critical conditions including kidney transplantation and amyotrophic lateral sclerosis. A webcast of the presentation will be available afterwards on the company’s website.
Read more →ELDN▼ -10.4%on this news
Eledon Reports Updated Data from Ongoing Phase 1b Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney Transplantation
Eledon Pharmaceuticals reported favorable results from its ongoing Phase 1b trial evaluating tegoprubart for preventing rejection in kidney transplantation. Data from 11 participants demonstrated that tegoprubart was generally safe, well tolerated, and effective in preventing transplant rejection, with kidney function measured through eGFR showing positive outcomes. The company aims to continue advancing its clinical trials, including a Phase 2 study initiated earlier this year. The results were presented at the American Society of Nephrology Kidney Week 2023 in Philadelphia.
Read more →ELDN▼ -10.4%on this news
attractive target for non-lymphocyte depleting, immunomodulatory therapeutic intervention. The Company is building upon a deep historical knowledge of anti-CD40 Ligand biology to conduct preclinical and clinical studies
Eledon Pharmaceuticals reported positive results from its ongoing Phase 1b trial evaluating tegoprubart for preventing kidney transplant rejection. The data from 11 participants showed that the drug was generally safe and well-tolerated, with no severe adverse effects commonly associated with standard treatment. Importantly, aggregate mean eGFR levels exceeded 70 mL/min/1.73m2, indicating effective protection of kidney function. The company plans to continue advancing its clinical program, including the ongoing Phase 2 BESTOW study.
Read more →ELDNThe ALS Therapy Keeping the Human Pig Heart Transplant Pumping
The article discusses the ongoing developments in organ transplantation, specifically focusing on the role of ALS therapy in supporting human pig heart transplants. It highlights the transformative potential of such therapies in improving patient outcomes. However, it lacks specific details or recent updates regarding clinical trials or patient stories.
Read more →ELDNMilestone Pig-to-Human Heart Transplant May Pave the Way for Broader Trial
A significant milestone has been reached in the field of organ transplantation with a successful pig-to-human heart transplant. This achievement may lead to broader clinical trials, offering hope for patients in need of organ transplants. The advancement highlights the potential of xenotransplantation as a viable solution to organ shortages.
Read more →ELDNEledon Pharmaceuticals Strengthens Leadership Team with Appointment of Eliezer Katz, M.D., FACS as Chief Medical Officer
Eledon Pharmaceuticals has appointed Eliezer Katz, M.D., FACS as the new Chief Medical Officer, overseeing the company's clinical development programs. Katz has extensive experience in surgical transplantation and clinical trial design, previously serving as Chief Medical Officer at eGenesis. He aims to contribute to the development of tegoprubart, Eledon's lead compound, which targets organ rejection prevention. His background includes roles at several biotech companies and significant involvement in regulatory approvals for therapies associated with transplantation and autoimmune conditions.
Read more →ELDNEledon Pharmaceuticals to Present Data from Ongoing Phase 1b Trial of Tegoprubart in Patients Undergoing Kidney Transplantation at the American Society of Nephrology Kidney Week 2023 Annual Meeting
Eledon Pharmaceuticals has announced that they will present data from their Phase 1b trial of tegoprubart at the American Society of Nephrology's Kidney Week 2023 Annual Meeting in Philadelphia. The poster presentation will focus on the drug's potential in preventing rejection in kidney transplantation. The session is scheduled for November 2, 2023, and will feature research shared by Eledon's President and Chief Scientific Officer, Steve Perrin. Following the presentation, the poster will be made available on Eledon's investor relations website.
Read more →ELDNJames Robinson
James Robinson has joined the Board of Directors at Eledon Pharmaceuticals as of October 2023. He has a robust background in the biopharmaceutical sector, having served as CEO at various companies, including A2 Biotherapeutics and Urovant Sciences. His experience includes leading successful product launches and overseeing significant revenue growth.
Read more →ELDNBryan Smith
Bryan Smith has been appointed as General Counsel, Corporate Secretary, and Chief Compliance Officer of Eledon since April 2021. He has a strong background in legal and compliance functions, having previously worked at Urovant Sciences and Allergan. Smith's experience includes leadership roles and litigation, showcasing his expertise in corporate governance.
Read more →ELDNSteven Perrin, PhD
Dr. Steven Perrin has been a member of the Board of Directors at Eledon Pharmaceuticals since September 2020. He previously founded Anelixis Therapeutics and has over 20 years of experience in drug development. Perrin has collaborated with the ALS Therapy Development Institute to advance ALS drug programs and holds a Ph.D. from Boston University Medical Center.
Read more →ELDN▲ +9.7%on this newsshared move
John S. McBride
Mr. John S. McBride has been a member of the Board of Directors at Eledon Pharmaceuticals since May 2017. He has a robust background in the biopharma industry, having served in key roles at several companies, including Chief Operating Officer and Chief Financial Officer at Tokai Pharmaceuticals. His experience spans strategic planning and business development in life sciences.
Read more →ELDN▲ +9.7%on this newsshared move
Paul Little
Paul Little has been the Chief Financial Officer of Eledon since March 2021, bringing over 30 years of experience in finance and operations. He previously held CFO roles at Sientra Inc. and Candela Medical, where he drove significant organizational efficiencies and revenue growth. His background includes key financial leadership positions at Allergan and ConAgra Brands.
Read more →ELDNThird
Eledon is dedicated to improving lives through organ transplants, emphasizing their mission of 'One Transplant for Life.' The company showcases various aspects of its operations, including patient stories, clinical trials, and its scientific approach. Eledon aims to provide ongoing support and care for transplant recipients.
Read more →ELDNSecond
Eledon focuses on organ transplantation with a mission of 'One Transplant for Life.' The company emphasizes its commitment to transforming lives through innovative clinical trials and patient stories. Their website provides extensive information on their science, pipeline, leadership, and governance, as well as investor resources and events.
Read more →ELDNFirst
Eledon is focused on organ transplantation, emphasizing their commitment to improving lives through innovative solutions. Their mission revolves around providing one transplant for life, showcasing a dedication to patient care and scientific advancement. The article outlines various aspects of the company's operations, including clinical trials and corporate governance.
Read more →ELDN▲ +13.1%on this newsshared move
Eledon Pharmaceuticals Appoints Kidney Transplant Specialist Dr. Allan Douglas Kirk to Board of Directors
Eledon Pharmaceuticals has appointed Dr. Allan Douglas Kirk, a renowned kidney transplant specialist, to its Board of Directors. Dr. Kirk's extensive experience in organ transplantation and immunology is expected to enhance Eledon's clinical development of tegoprubart, an anti-CD40L antibody currently in Phase 2 trials aimed at preventing organ rejection. His appointment comes at a critical time as the company seeks to address significant unmet needs in transplant patient care. Eledon continues to focus on developing innovative therapies to improve transplant outcomes.
Read more →ELDN▲ +13.1%on this newsshared move
June Lee, MD
Dr. June Lee has been a member of the Board of Directors at Eledon Pharmaceuticals since December 2020. She has held significant positions in various biotech firms, including serving as CEO of Esker Therapeutics and Chief Development Officer at MyoKardia, contributing to its acquisition by Bristol Myers Squibb. Dr. Lee has a strong academic background and is involved in several advisory boards and councils.
Read more →ELDN▲ +13.1%on this newsshared move
David Hovland, PhD
Dr. David Hovland has been the Chief Regulatory Officer at Eledon since April 2021, overseeing Regulatory, Quality, and Safety functions. With over 20 years of experience in the pharmaceutical industry, he has played a significant role in the development and registration of various pharmaceutical products. His previous positions include senior roles at Urovant Sciences and Allergan.
Read more →ELDN▲ +13.1%on this newsshared move
Allan Kirk, MD, PhD
Dr. Allan Kirk has joined the Board of Directors at Eledon Pharmaceuticals, Inc. as of October 2023. He is a distinguished professor and chairman at Duke University School of Medicine, with a focus on transplant surgery and immunology. His extensive background includes leadership roles at Emory University and significant contributions to clinical trials and research in transplant rejection therapies.
Read more →ELDN▲ +13.1%on this newsshared move
John Herberger
John Herberger has been the Vice President of Technical Operations at Eledon since May 2022. He has a rich background in the biopharma industry, having held significant roles at Spark Therapeutics and Amgen. His expertise includes drug delivery, formulation, and technology transfer. Herberger also has a history of involvement in academic advisory councils.
Read more →ELDNMarina Escudero
Marina Escudero has been appointed as Vice President and Head of Clinical Operations at Eledon, effective January 2024. With over 20 years of experience in pharmaceutical R&D, she has played a significant role in drug development across various phases. Previously, she held leadership positions at Leap Therapeutics and Kiniksa Pharmaceuticals, and founded Caliber Clinical Consulting.
Read more →ELDN▲ +10.5%on this news· ran to +36% by day 3shared move
Jan Hillson, MD
Dr. Jan Hillson has been a board member at Eledon Pharmaceuticals since July 2021. She is currently the Senior Vice President of Clinical Development at Provention Bio, which was acquired by Sanofi for $2.9 billion. Dr. Hillson has held senior roles at various biotech firms and is also a licensed rheumatologist.
Read more →ELDNAmanda Skeens’s Story
Amanda Skeens was diagnosed with IgAN in 2007, facing potential kidney failure. After years of remission, she experienced a flare-up, prompting her to seek aggressive treatment and support. Amanda became a Patient Ambassador, advocating for others while searching for a living donor. Ultimately, a cousin stepped up to donate, providing her peace of mind as she navigates her health journey.
Read more →ELDNAugie Nieto’s Story
Augie Nieto, a prominent figure in the fitness industry, was diagnosed with ALS in 2005. In response, he co-founded Augie's Quest to Cure ALS, raising over $150 million for research. Despite his passing in February 2023, his legacy continues through his wife Lynne, who now leads the initiative to find a cure.
Read more →ELDNCurtis Warfield’s Story
Curtis Warfield's journey through kidney disease began in 2005 with abnormal lab results. Diagnosed with focal segmental glomerulosclerosis and stage 3 kidney disease, he faced kidney failure by 2014. After a successful transplant in 2016, he became an advocate for kidney disease awareness and equity, focusing on improving patient education and access to care.
Read more →ELDNDavid-Alexandre C. Gros, MD
Dr. David-Alexandre C. Gros has been the CEO of Eledon Pharmaceuticals since September 2020. He previously co-founded Imbria Pharmaceuticals and held key positions at Neurocrine Biosciences and Alnylam Pharmaceuticals. Dr. Gros has a notable background in healthcare investment banking and consulting, and he also serves as Executive Chairman of a French pasta manufacturer.
Read more →ELDNKeith A. Katkin
Keith A. Katkin has been the Chairman of Eledon Pharmaceuticals since May 2017, following its acquisition of Otic Pharma. He has a notable history in the biopharmaceutical sector, including leadership roles at Urovant Sciences and Avanir Pharmaceuticals, where he facilitated significant growth and sales. Katkin holds an M.B.A. from UCLA and a B.S. from Indiana University.
Read more →ELDNAnother Person Just Got a Pig Heart. Scientists Have a Plan to Make It Last
The article discusses the recent advancements in xenotransplantation, particularly focusing on the successful transplantation of a pig heart into a human. Scientists are now developing strategies to enhance the longevity and functionality of such organs in human recipients. This breakthrough could potentially transform organ transplantation and address the shortage of human organs.
Read more →ELDNEledon Pharmaceuticals Announces Use of Tegoprubart anti-CD40L Antibody in Second-ever Transplant of Genetically Modified Heart from a Pig to a Human
Eledon Pharmaceuticals announced the successful use of its investigational anti-CD40L antibody, tegoprubart, in a groundbreaking procedure where a genetically modified pig heart was transplanted into a human at the University of Maryland Medical Center. This transplant marks only the second instance of such a procedure and is aimed at addressing the critical shortage of available organs. Tegoprubart is designed to prevent organ rejection, and the company is advancing multiple research efforts related to its use in xenotransplantation and other transplant settings. The procedure exemplifies ongoing advancements in transplantation therapies, despite the inherent risks involved.
Read more →ELDNGenetically Modified Pig’s Heart Is Transplanted Into a Second Patient
A genetically modified pig's heart has been successfully transplanted into a second patient, marking a significant advancement in xenotransplantation. This procedure holds promise for addressing the organ shortage crisis. The success of the first transplant has paved the way for further developments in this innovative field.
Read more →ELDNEledon Pharmaceuticals to Participate at the 2023 Cantor Fitzgerald Global Healthcare Conference
Eledon Pharmaceuticals, Inc. (NASDAQ: ELDN) announced its participation in the Cantor Fitzgerald Global Healthcare Conference scheduled for September 27, 2023. During the event, CEO David-Alexandre C. Gros, M.D., and President Steve Perrin, Ph.D., will present on the company's initiatives. Eledon focuses on developing therapies to address organ transplant rejection and amyotrophic lateral sclerosis (ALS), with their lead compound being tegoprubart. The conference participation highlights the company's commitment to advancing their pipeline and engaging with investors.
Read more →ELDNEledon Pharmaceuticals Appoints Industry Veteran James Robinson to its Board of Directors
Eledon Pharmaceuticals has appointed James Robinson to its Board of Directors, effective October 1, 2023. Robinson, a seasoned executive with over 30 years in the biopharmaceutical industry, previously led Urovant Sciences and has significant experience in solid organ transplant. His addition comes as Eledon seeks to advance its innovative treatment, tegoprubart, aimed at improving outcomes for kidney transplant patients. CEO David-Alexandre C. Gros expresses optimism about the synergy between Robinson's expertise and Eledon's mission.
Read more →ELDN▼ -11.9%on this newsshared move
Eledon Pharmaceuticals Announces Publication of Data Showing Treatment with Tegoprubart Promotes Kidney and Islet Allograft Survival and Function in Nonhuman Primates
Eledon Pharmaceuticals announced the publication of a study demonstrating that tegoprubart effectively promotes kidney and islet allograft survival and function in nonhuman primates. The study, published in Science Translational Medicine, indicates the treatment's potential as an immunomodulatory agent for organ transplantation. Eledon has initiated the BESTOW study to further evaluate tegoprubart in human kidney transplantation, planning to present updated data at upcoming conferences. The company aims to leverage this finding to establish tegoprubart as a critical therapy in organ transplant management.
Read more →ELDNEledon Pharmaceuticals Announces First Participant Dosed in Phase 2 BESTOW Trial Evaluating Tegoprubart for the Prevention of Rejection in Kidney Transplantation
Eledon Pharmaceuticals announced the dosing of the first participant in its Phase 2 BESTOW trial, which will evaluate the anti-CD40 ligand antibody tegoprubart for preventing organ rejection in kidney transplants. The trial aims to enroll around 120 participants and will focus on comparing tegoprubart to the standard calcineurin inhibitor tacrolimus. Eledon has reported promising results from its earlier Phase 1b trial, with consistent graft function and no instances of acute rejection observed. The company expects to provide additional data from both trials over the next 18 months.
Read more →ELDNEledon Pharmaceuticals Announces Dosing of 10th Patient in Ongoing Phase 1b Trial Evaluating Tegoprubart in Patients Undergoing Kidney Transplantation
Eledon Pharmaceuticals has announced the dosing of the 10th patient in its ongoing Phase 1b trial evaluating the drug tegoprubart for kidney transplantation. This milestone signifies progress toward the second tranche of funding, linked to achieving clinical milestones. Additionally, the company plans to report updated interim data at the ASN Kidney Week in November 2023. Eledon aims to improve immunosuppressive regimens for kidney transplant patients, indicating a demand-driven trial enrollment.
Read more →ELDNEledon Pharmaceuticals Reports Second Quarter 2023 Operating and Financial Results
Eledon Pharmaceuticals reported its second quarter 2023 results, highlighting significant progress in its clinical trials for tegoprubart, an immunosuppressive therapy for kidney transplantation. The company has successfully dosed nine patients in its Phase 1b trial and expects to present updated data in the fourth quarter. Eledon also raised up to $185 million in financing which will support its upcoming Phase 2 BESTOW trial. Despite a net loss of $9.6 million in the quarter, the financial position improved with cash and equivalents increasing to $71.4 million.
Read more →ELDNEledon Pharmaceuticals to Present at Jefferies Healthcare Conference
Eledon Pharmaceuticals announced that its CEO, David-Alexandre C. Gros, M.D., will present a company overview at the Jefferies Healthcare Conference on June 9, 2023. This presentation is an opportunity for Eledon to highlight its advancements and the potential of its lead compound, tegoprubart, which aims to protect transplanted organs and treat ALS. A webcast of the presentation will be available for those interested in the company's updates.
Read more →ELDNEledon Pharmaceuticals Reports First Quarter 2023 Operating and Financial Results
Eledon Pharmaceuticals reported its first quarter 2023 results, highlighting significant progress in its Phase 1b trial of tegoprubart for kidney transplantation. Early results from three participants indicated effective prevention of acute rejection and positive kidney function. Additionally, the company secured up to $185 million in financing to support the upcoming Phase 2 BESTOW trial. Despite a reported net loss of $10.8 million, the company is optimistic about its financial position and ongoing clinical developments in its pipeline.
Read more →ELDN▲ +6.3%on this news
Eledon Pharmaceuticals to Report First Quarter 2023 Financial Results on Thursday, May 11, 2023
Eledon Pharmaceuticals has announced plans to release its financial results for Q1 2023 on May 11, 2023. Following the results, the management team will hold a conference call and webcast to discuss the findings at 4:30 p.m. ET. The company focuses on developing therapies that target the CD40 Ligand pathway and is advancing its lead compound, tegoprubart. This event will provide insights into Eledon's performance and future direction.
Read more →ELDN▲ +9.5%on this news· ran to +20% by day 3shared move
Eledon Pharmaceuticals Announces up to $185 Million Financing to Advance Tegoprubart Kidney Transplantation Clinical Trials
Eledon Pharmaceuticals has announced a financing agreement worth up to $185 million to support its clinical trials for tegoprubart, a treatment aimed at preventing rejection in kidney transplant patients. The financing includes an initial $35 million upfront and additional funding contingent on achieving clinical milestones. Led by BVF Partners LP and Armistice Capital with the participation of Sanofi, the funds are expected to finance Eledon's operations through the completion of critical Phase 2 trials. The company is focused on expanding the therapeutic options available for organ transplant patients.
Read more →ELDN▲ +9.5%on this news· ran to +20% by day 3shared move
including: risks related to the private placement, risks relating to the safety and efficacy of our drug candidates; risks relating to clinical development timelines, including interactions with regulators and clinical s
Eledon Pharmaceuticals has announced a significant financing deal worth up to $185 million, which aims to support the advancement of its drug candidate, tegoprubart, in clinical trials for kidney transplantation. The initial upfront financing of $35 million is accompanied by additional milestone-based funding, intended to ensure the completion of the Phase 2 BESTOW trial. The company highlights the strong backing it has received from notable investors, including Sanofi. Despite the positive funding news, Eledon faces several risks, including challenges related to clinical development timelines and the safety of its drug candidates.
Read more →ELDN▼ -6%on this news· ran to -25% by day 3
Eledon Reports Data from Ongoing Phase 1b Trial Evaluating Tegoprubart in Patients Undergoing Kidney Transplantation at World Congress of Nephrology
Eledon Pharmaceuticals announced results from its ongoing Phase 1b trial of tegoprubart in kidney transplant patients at the World Congress of Nephrology. The initial results from three participants showed no acute rejection incidents, with strong graft function indicated by mean eGFRs above 70. Safety data from a Phase 2a trial for IgA Nephropathy demonstrated that tegoprubart is well tolerated with no severe adverse events. Despite some participants withdrawing from the trial for various reasons, the preliminary findings highlight the potential effectiveness of tegoprubart in preventing organ rejection.
Read more →ELDN▲ +5.9%on this news· ran to -18% by day 3shared move
Eledon Pharmaceuticals Reports Fourth Quarter and Full-Year 2022 Operating and Financial Results
Eledon Pharmaceuticals reported its fourth quarter and full-year 2022 results, highlighting its strategic focus on kidney transplantation programs, particularly with tegoprubart. Initial positive data from a Phase 1b trial will be presented at the World Congress of Nephrology. The company indicated a net loss significantly due to a goodwill impairment charge while announcing upcoming safety data from its ongoing trials. Eledon aims to prioritize growth in kidney transplant treatment while managing resources effectively.
Read more →ELDNEledon to Present Data from Ongoing Phase 1b Trial Evaluating Tegoprubart in Kidney Transplantation at the World Congress of Nephrology 2023
Eledon Pharmaceuticals has announced plans to present data from its ongoing Phase 1b trial of tegoprubart at the World Congress of Nephrology 2023 in Bangkok, Thailand. The presentations will include safety and efficacy data related to kidney transplantation and findings from a high-dose cohort in a Phase 2a trial for IgA Nephropathy. The poster sessions, led by Chief Medical Officer Jeff Bornstein, are scheduled for March 31 and April 1, 2023, respectively. The data presented aims to highlight emerging results that may be significant in the field of nephrology.
Read more →ELDNEledon Pharmaceuticals to Report Fourth Quarter and Full Year 2022 Financial Results on Thursday, March 30, 2023
Eledon Pharmaceuticals has announced that it will release its financial results for the fourth quarter and full year of 2022 on March 30, 2023. Following the results, the company will host a conference call and webcast to discuss the findings with investors. Eledon is focused on developing treatments targeting the CD40 Ligand pathway, with its lead compound being tegoprubart for various serious medical conditions.
Read more →ELDNEledon Pharmaceuticals to Present at SVB Securities Global Biopharma Conference
Eledon Pharmaceuticals is set to present at the SVB Securities Global Biopharma Conference on February 15, 2023, led by CEO David-Alexandre C. Gros. This event highlights the company's ongoing development efforts in targeting the CD40 Ligand pathway for potential treatments, particularly in organ transplants and autoimmune diseases. The webcast will be available for those who cannot attend the live session, demonstrating Eledon's commitment to transparency and investor engagement.
Read more →ELDNAbout Eledon Pharmaceuticals and tegoprubart Eledon Pharmaceuticals is a clinical stage biotechnology company using its expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop potential treat
Eledon Pharmaceuticals has announced a strategic focus on advancing its drug, tegoprubart, specifically for kidney transplantation. The company continues to enroll patients in a Phase 1b trial and plans to initiate a Phase 2 trial, BESTOW, to assess its efficacy in preventing transplant rejection. Eledon has deprioritized its IgA Nephropathy program to better allocate resources for kidney transplant initiatives, demonstrating confidence in the unmet medical need and market opportunity for tegoprubart in this field.
Read more →ELDNEledon Pharmaceuticals Provides Business and Pipeline Updates
Eledon Pharmaceuticals has announced a strategic shift to prioritize its kidney transplantation program involving tegoprubart. The company will continue its Phase 1b trial and plans to initiate the Phase 2 BESTOW trial for preventing rejection in kidney transplant patients. However, the development of tegoprubart for IgA Nephropathy has been deprioritized, and the islet cell transplantation program is being discontinued. Despite these adjustments, Eledon reports sufficient financial resources to support its operations into 2024.
Read more →ELDN▲ +8.3%on this news
Eledon Pharmaceuticals Reports Third Quarter 2022 Operating and Financial Results Received FDA clearance of IND application to evaluate tegoprubart in a Phase 2 trial for the prevention of rejection in patients receiving
Eledon Pharmaceuticals Reports Third Quarter 2022 Operating and Financial Results Received FDA clearance of IND application to evaluate tegoprubart in a Phase 2 trial for the prevention of rejection in patients receiving a kidney transplant Dosed initial two patients in ex-U.S.
Read more →ELDN▼ -6.4%on this news
Eledon Pharmaceuticals to Report Third Quarter 2022 Financial Results on Monday, November 14, 2022
IRVINE, Calif., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), today announced that it plans to release financial results for the third quarter ended September 30, 2022 on Monday, November 14, after the close of trading. Eledon’s managem
Read more →ELDNEledon Pharmaceuticals Announces Upcoming Presentations at ASN’s Kidney Week 2022 and NEALS
IRVINE, Calif., Oct. 24, 2022 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), today announced that the Company will present two posters at the upcoming American Society of Nephrology’s (ASN) Kidney Week 2022 being held November 3-6, 2022, in Orlando, F
Read more →ELDNEledon Pharmaceuticals to Participate in Two Upcoming Conferences
IRVINE, Calif., Oct. 03, 2022 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), today announced that senior management will participate in two upcoming conferences: A panel discussion with Steven Perrin, Ph.D., President and Chief Scientific Officer, ti
Read more →ELDN▼ -7.9%on this news
Eledon Pharmaceuticals to Present at Ladenburg Thalmann Healthcare Conference
IRVINE, Calif., Sept. 22, 2022 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), today announced that David-Alexandre C. Gros, Chief Executive Officer, will participate in a fireside chat at the Ladenburg Thalmann Healthcare Conference on Thursday, Septe
Read more →ELDNEledon Pharmaceuticals Receives FDA Clearance of IND Application to Evaluate Tegoprubart in IgA Nephropathy
IRVINE, Calif., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), today announced that the U.S. Food and Drug Administration (FDA) has cleared the company's Investigational New Drug (IND) application to evaluate tegoprubart for the treatme
Read more →ELDNEledon Pharmaceuticals to Participate in Two Upcoming Investor Conferences
IRVINE, Calif., Aug. 29, 2022 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), today announced that senior management will participate in two upcoming investor conferences: A fireside chat at the virtual Gilmartin Group Emerging Growth Company Showcase
Read more →ELDNEledon Pharmaceuticals Reports Second Quarter 2022 Operating and Financial Results
Received FDA clearance of IND application for Phase 2 trial evaluating tegoprubart for the prevention of rejection in kidney transplant recipients First patient dosed in Phase 1b trial evaluating tegoprubart for the prevention of rejection in kidney transplant recipients in Cana
Read more →ELDNEledon Pharmaceuticals to Report Second Quarter 2022 Financial Results on Thursday, August 11, 2022
Management to host conference call and webcast at 4:30 pm ET IRVINE, Calif., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a patient-focused clinical stage biopharmaceutical company committed to the development of innovative and impact
Read more →ELDNEledon Pharmaceuticals Receives FDA Clearance of IND Application to Evaluate Tegoprubart for the Prevention of Rejection in Kidney Transplant Recipients
IRVINE, Calif., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a patient-focused clinical stage biopharmaceutical company committed to the development of innovative and impactful treatments for organ and cell transplantation, autoimmune
Read more →ELDNEledon Pharmaceuticals Announces the First Patient Dosed in Phase 1b Trial Evaluating Tegoprubart in Kidney Transplantation
IRVINE, Calif., July 18, 2022 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a patient-focused clinical stage biopharmaceutical company committed to the development of innovative and impactful treatments for organ and cell transplantation, autoimmune
Read more →ELDNEledon Pharmaceuticals Announces Orphan Drug Designation Granted to Tegoprubart for the Prevention of Allograft Rejection in Pancreatic Islet Cell Transplantation
IRVINE, Calif., June 09, 2022 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a patient-focused clinical stage biopharmaceutical company committed to the development of innovative and impactful treatments for organ and cell transplantation, autoimmune
Read more →ELDNEledon Pharmaceuticals to Present at the Jefferies Healthcare Conference
IRVINE, Calif., June 02, 2022 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a patient-focused clinical stage biopharmaceutical company committed to the development of innovative and impactful treatments for organ and cell transplantation, autoimmune
Read more →ELDN▼ -10.6%on this newsshared move
Eledon Announces Positive Topline Results from Phase 2a Trial of Tegoprubart Demonstrating Safety, Target Engagement, and Biomarker Response in Patients Living with Amyotrophic Lateral Sclerosis • Tegoprubart was
Eledon Announces Positive Topline Results from Phase 2a Trial of Tegoprubart Demonstrating Safety, Target Engagement, and Biomarker Response in Patients Living with Amyotrophic Lateral Sclerosis -Tegoprubart was well-tolerated, with no drug-related serious adverse events -Dos
Read more →ELDNEledon Pharmaceuticals Reports First Quarter 2022 Operating and Financial Results Topline data for Phase 2a tegoprubart study in amyotrophic lateral sclerosis (ALS) anticipated in June 2022 First patient dosed in Phase 2
Eledon Pharmaceuticals Reports First Quarter 2022 Operating and Financial Results Topline data for Phase 2a tegoprubart study in amyotrophic lateral sclerosis (ALS) anticipated in June 2022 First patient dosed in Phase 2a trial evaluating tegoprubart in IgA Nephropathy with ini
Read more →ELDN▼ -12%on this newsshared move
Eledon Pharmaceuticals Announces First Patient Dosed in Phase 2a Trial Evaluating Tegoprubart in IgA Nephropathy
IRVINE, Calif., May 09, 2022 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. ("Eledon") (NASDAQ: ELDN), a patient-focused clinical stage biopharmaceutical company committed to the development of innovative and impactful treatments for organ and cell transplantation, autoimmune c
Read more →ELDN▼ -5.4%on this newsshared move
Eledon Pharmaceuticals to Report First Quarter 2022 Financial Results on Thursday, May 12, 2022
IRVINE, Calif., May 05, 2022 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a patient-focused clinical stage biopharmaceutical company committed to the development of innovative and impactful treatments for organ and cell transplantation, autoimmune c
Read more →ELDNEledon Pharmaceuticals to Participate in LifeSci Partners Immunology & Inflammation Symposium
IRVINE, Calif., May 03, 2022 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a patient-focused clinical stage biopharmaceutical company committed to the development of innovative and impactful treatments for organ and cell transplantation, autoimmune c
Read more →ELDN▼ -8.3%on this news
Eledon Pharmaceuticals to Participate in 18th Annual Noble Capital Markets Investor Conference
IRVINE, Calif., April 18, 2022 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a patient-focused clinical stage biopharmaceutical company committed to the development of innovative and impactful treatments for organ and cell transplantation, autoimmune
Read more →ELDNEledon to Host Virtual R&D Day on Thursday, April 28, 2022
IRVINE, Calif., April 14, 2022 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a patient-focused clinical stage biopharmaceutical company committed to the development of innovative and impactful treatments for organ and cell transplantation, autoimmune
Read more →ELDNEledon Pharmaceuticals Reports Fourth Quarter and Full-Year 2021 Operating and Financial Results
Topline data from Phase 2a trial of tegoprubart in ALS expected in 2Q 2022 Ongoing clinical studies evaluating tegoprubart in kidney transplantation, IgA nephropathy, and islet cell transplantation with initial readouts anticipated in late 2022 Cash balance of $84.8M, sufficien
Read more →ELDNEledon Pharmaceuticals Reports Fourth Quarter and Full-Year 2021 Operating and Financial Results Topline data from Phase 2a trial of tegoprubart in ALS expected in 2Q 2022 Ongoing clinical s
Eledon Pharmaceuticals Reports Fourth Quarter and Full-Year 2021 Operating and Financial Results Topline data from Phase 2a trial of tegoprubart in ALS expected in 2Q 2022 Ongoing clinical studies evaluating tegoprubart in kidney transplantation, IgA nephropathy, and islet cell
Read more →ELDNEledon Pharmaceuticals to Report Fourth Quarter and Full Year 2021 Financial Results on Thursday, March 24, 2022
IRVINE, Calif., March 17, 2022 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a patient-focused clinical stage biopharmaceutical company committed to the development of innovative and impactful treatments for organ and cell transplantation, autoimmune
Read more →ELDNEledon Pharmaceuticals Provides Corporate Update and 2022 Outlook
Completed enrollment of all four cohorts in ongoing Phase 2a study with tegoprubart (AT-1501) in Amyotrophic Lateral Sclerosis (ALS) Announces USAN Approval of Generic Name “tegoprubart” for lead asset AT-1501 Catalyst-rich period ahead with four clinical trial readouts anticip
Read more →ELDNEledon Pharmaceuticals to Participate in 11th Annual SVB Leerink Global Healthcare Conference
IRVINE, Calif., Feb. 08, 2022 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a patient-focused clinical stage biopharmaceutical company committed to the development of innovative and impactful treatments for organ and cell transplantation, autoimmune
Read more →ELDNEledon Pharmaceuticals to Participate in January 2022 Investor Conferences
IRVINE, Calif., Dec. 27, 2021 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a patient-focused clinical stage biopharmaceutical company committed to the development of innovative and impactful treatments for organ and cell transplantation, autoimmune
Read more →ELDNEledon Pharmaceuticals Reports Third Quarter 2021 Operating and Financial Results Nearing full enrollment in ALS Phase 2 Study; topline data expected 1H 2022 Received Investigational New Drug ("IND") clearance from the F
Eledon Pharmaceuticals Reports Third Quarter 2021 Operating and Financial Results Nearing full enrollment in ALS Phase 2 Study; topline data expected 1H 2022 Received Investigational New Drug ("IND") clearance from the FDA for AT-1501 in islet cell transplantation in the U.S.
Read more →ELDNEledon Pharmaceuticals CEO David-Alexandre C. Gros, M.D., to Present at CareDx Virtual Transplant Innovation Day during ASN Kidney Week 2021
IRVINE, Calif., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a clinical stage biopharmaceutical company focused on developing targeted medicines for persons living with autoimmune disease, requiring an organ or cell-based transplant, o
Read more →ELDNEledon Pharmaceuticals Announces Participation in November Conferences
IRVINE, Calif., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a clinical stage biopharmaceutical company focused on developing targeted medicines for persons living with autoimmune disease, requiring an organ or cell-based transplant, o
Read more →ELDNEledon Pharmaceuticals to Release Third Quarter Financial Results on Thursday, November 11, 2021
IRVINE, Calif., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals (“Eledon”) (NASDAQ: ELDN), a clinical stage biopharmaceutical company focused on developing life-changing, targeted medicines for persons living with autoimmune disease, requiring an organ or cell-based tran
Read more →ELDNEledon Pharmaceuticals Announces Presentation on AT-1501 at the Virtual 2021 Northeast Amyotrophic Lateral Sclerosis Consortium
IRVINE, Calif., Oct. 07, 2021 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a clinical stage biopharmaceutical company focused on developing targeted medicines for persons living with autoimmune disease, requiring an organ or cell-based transplant, o
Read more →ELDNEledon Pharmaceuticals Announces Upcoming Presentation on AT-1501 at the Virtual 2021 International Pancreas and Islet Transplantation Association Congress
IRVINE, Calif., Oct. 05, 2021 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a clinical stage biopharmaceutical company focused on developing targeted medicines for persons living with autoimmune disease, requiring an organ or cell-based transplant, o
Read more →ELDNEledon Pharmaceuticals to Present at Two Investor Conferences in September
IRVINE, Calif., Sept. 01, 2021 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a clinical stage biopharmaceutical company focused on developing targeted medicines for persons living with autoimmune disease, requiring an organ or cell-based transplant,
Read more →ELDNEledon Pharmaceuticals Reports Second Quarter 2021 Operating and Financial Results Received approval from Health Canada to initiate a clinical trial of AT-1501 in kidney transplantation; company expects to initiate trial
Eledon Pharmaceuticals Reports Second Quarter 2021 Operating and Financial Results Received approval from Health Canada to initiate a clinical trial of AT-1501 in kidney transplantation; company expects to initiate trial in Q4 with initial data in late 2022 Reached agreement wi
Read more →ELDNEledon Pharmaceuticals to Release Second Quarter Financial Results on Thursday, August 12, 2021
IRVINE, Calif., Aug. 02, 2021 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals (“Eledon”) (NASDAQ: ELDN), a clinical stage biopharmaceutical company focused on developing life-changing, targeted medicines for persons living with autoimmune disease, requiring an organ or cell-based tran
Read more →ELDNEledon Pharmaceuticals Receives Health Canada Approval to Commence Human Trials to Evaluate AT-1501 in Kidney Transplantation
Interim data expected in late 2022 in a multicenter, open label study to replace tacrolimus with AT-1501 IRVINE, Calif., July 26, 2021 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a clinical stage biopharmaceutical company focused on developing tar
Read more →ELDNEledon Pharmaceuticals Appoints Jan Hillson, M.D., to its Board of Directors
IRVINE, Calif., July 02, 2021 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a clinical stage biopharmaceutical company focused on developing targeted medicines for persons living with autoimmune disease, requiring an organ or cell-based transplant, o
Read more →ELDNEledon Pharmaceuticals to Present at the Virtual Ladenburg Thalmann Healthcare Conference
IRVINE, Calif., June 29, 2021 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a clinical stage biopharmaceutical company focused on developing targeted medicines for persons living with autoimmune disease, requiring an organ or cell-based transplant, o
Read more →ELDNEledon Pharmaceuticals to Present at the 2021 Jefferies Virtual Healthcare Conference
IRVINE, Calif., May 18, 2021 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a clinical stage biopharmaceutical company focused on developing targeted medicines for persons living with autoimmune disease, requiring an organ or cell-based transplant, or
Read more →ELDNEledon Pharmaceuticals Reports First Quarter 2021 Operating and Financial Results Continued enrollment in Phase 2 clinical trial of AT-1501 in amyotrophic lateral sclerosis (ALS) Strengthens senior leadership team with f
Eledon Pharmaceuticals Reports First Quarter 2021 Operating and Financial Results Continued enrollment in Phase 2 clinical trial of AT-1501 in amyotrophic lateral sclerosis (ALS) Strengthens senior leadership team with four key additions IRVINE, Calif., May 13, 2021 - Eledon P
Read more →ELDNEledon Pharmaceuticals Announces Upcoming Presentations on AT-1501 at the Virtual 2021 American Transplant Congress
IRVINE, Calif., May 05, 2021 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a clinical stage biopharmaceutical company focused on developing targeted medicines for persons living with autoimmune disease, requiring an organ or cell-based transplant, or
Read more →ELDNEledon Pharmaceuticals to Release First Quarter Financial Results on Thursday, May 13, 2021
IRVINE, Calif., May 04, 2021 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals (“Eledon”) (NASDAQ: ELDN), a clinical stage biopharmaceutical company focused on developing life-changing, targeted medicines for persons living with autoimmune disease, requiring an organ or cell-based trans
Read more →ELDNEledon Pharmaceuticals Announces Update on Development Strategy for AT-1501 in Renal Transplantation
Eledon Pharmaceuticals Announces Update on Development Strategy for AT-1501 in Renal Transplantation IRVINE, Calif., April 26, 2021 - Eledon Pharmaceuticals, Inc. ("Eledon") (NASDAQ: ELDN), a clinical stage biopharmaceutical company focused on developing targeted medicines for
Read more →ELDNEledon Pharmaceuticals Continues to Bolster Leadership Team with Addition of Two More Key Executives
IRVINE, Calif., April 19, 2021 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a clinical stage biopharmaceutical company focused on developing targeted medicines for persons living with autoimmune disease, requiring an organ or cell-based transplant,
Read more →ELDNEledon Pharmaceuticals Reports Fourth Quarter and Full-Year 2020 Operating and Financial Results
Continued enrollment in Phase 2 clinical trial of AT-1501 in amyotrophic lateral sclerosis (ALS) First patient to be enrolled in Phase 2 clinical trial of AT-1501 in islet cell transplantation for type 1 diabetes expected in Q2’21 Cash Balance of $114.2 million at December 31,
Read more →ELDNEledon Pharmaceuticals to Release Fourth Quarter and Full-Year Financial Results on Tuesday, March 30
IRVINE, Calif., March 23, 2021 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals (“Eledon”) (NASDAQ: ELDN), a clinical stage biopharmaceutical company focused on developing life-changing, targeted medicines for persons living with an autoimmune disease, requiring an organ or cell-based
Read more →ELDNEledon Pharmaceuticals Strengthens Leadership Team with Chief Medical Officer and Chief Financial Officer Hires
IRVINE, Calif., March 15, 2021 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a clinical stage biopharmaceutical company focused on developing life-changing, targeted medicines for persons undergoing organ or cellular transplantation, as well as those
Read more →ELDNEledon Pharmaceuticals to Present at H.C. Wainwright Global Life Sciences Conference
IRVINE, Calif., March 02, 2021 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a clinical stage biopharmaceutical company focused on developing life-changing, targeted medicines for persons undergoing organ or cellular transplantation, as well as those
Read more →ELDNEledon Pharmaceuticals to Present at 10th Annual SVB Leerink Global Healthcare Conference
IRVINE, Calif., Feb. 17, 2021 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a clinical stage biopharmaceutical company focused on developing life-changing, targeted medicines for persons undergoing organ or cellular transplantation, as well as those
Read more →ELDNEledon Pharmaceuticals to Participate in the Virtual Noble Capital Markets' Seventeenth Annual Investor / Equity Conference
IRVINE, Calif., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a clinical stage biopharmaceutical company focused on developing life-changing, targeted medicines for persons undergoing organ or cellular transplantation, as well as those
Read more →ELDNNovus Therapeutics Announces Name Change to Eledon Pharmaceuticals; Provides Corporate Update and Outlook Eledon to commence trading on the Nasdaq exchange under the ticker "ELDN" effective tomorrow
Therapeutics Announces Name Change to Eledon Pharmaceuticals; Provides Corporate Update and Outlook to commence trading on the Nasdaq exchange under the ticker "ELDN" effective tomorrow, is well financed to complete up to four Phase 2 clinical trials of lead candidate AT-1501,
Read more →ELDNNovus Therapeutics Announces Acquisition of Anelixis Therapeutics Acquisition includes lead clinical-stage compound AT-1501, a next generation anti-CD40L antibody, in development for organ and cellular transplantation, a
Novus Therapeutics Announces Acquisition of Anelixis Therapeutics Acquisition includes lead clinical-stage compound AT-1501, a next generation anti-CD40L antibody, in development for organ and cellular transplantation, autoimmune diseases, and neurodegenerative diseases Senio
Read more →ELDNNovus Therapeutics Reports First Quarter 2020 Financial Results
Novus Therapeutics Reports First Quarter 2020 Financial Results May 15, 2020 at 6:30 AM Eastern Time IRVINE, Calif. --(BUSINESS WIRE)-- Novus Therapeutics, Inc. (NASDAQ: NVUS), a specialty pharmaceutical company focused on developing products for patients with disorders of the
Read more →ELDNNovus Therapeutics Reports Fourth Quarter and Full-Year 2019 Financial Results Data from the fully enrolled phase 2a efficacy study in infants and children with acute otitis media to be announced by early June 2020
Novus Therapeutics Reports Fourth Quarter and Full-Year 2019 Financial Results Data from the fully enrolled phase 2a efficacy study in infants and children with acute otitis media to be announced by early June 2020 March 17, 2020 at 7:30 AM Eastern Time IRVINE, Calif. --(BUSIN
Read more →ELDNNovus Therapeutics Reports Third Quarter 2019 Financial Results -- Management to participate in two investor conferences in December 2019 -- -- Data from ongoing phase 2a study C-006 expected in the first half of 2020
Novus Therapeutics Reports Third Quarter 2019 Financial Results -- Management to participate in two investor conferences in December 2019 -- -- Data from ongoing phase 2a study C-006 expected in the first half of 2020 -- November 13, 2019 at 7:30 AM Eastern Time IRVINE, Calif
Read more →ELDNNovus Therapeutics Reports Second Quarter 2019 Financial Results
Novus Therapeutics Reports Second Quarter 2019 Financial Results August 13, 2019 at 4:05 PM Eastern Daylight Time IRVINE, Calif.--(BUSINESS WIRE)-- Novus Therapeutics, Inc. (NASDAQ: NVUS), a specialty pharmaceutical company focused on developing products for patients with disor
Read more →ELDNNovus Therapeutics Reports First Quarter 2019 Financial Results
Novus Therapeutics Reports First Quarter 2019 Financial Results May 14, 2019 at 4:05 PM Eastern Daylight Time IRVINE, Calif.--(BUSINESS WIRE)-- Novus Therapeutics, Inc. (NASDAQ: NVUS), a specialty pharmaceutical company focused on developing products for patients with disorders
Read more →ELDNNovus Therapeutics Announces $10.7 Million Registered Direct Offering Priced At-the-Market
Novus Therapeutics Announces $10.7 Million Registered Direct Offering Priced At-the-Market April 30, 2019 at 9:00 AM Eastern Daylight Time IRVINE, Calif. (BUSINESS WIRE) Novus Therapeutics, Inc. (NASDAQ: NVUS), a specialty pharmaceutical company focused on developing products f
Read more →ELDNNovus Therapeutics Announces Results of Two Single-Dose Phase 1 Studies of OP0201 OP0201 Was Safe and Well-Tolerated in Healthy Adults and Adults with Acute Otitis Media
Novus Therapeutics Announces Results of Two Single-Dose Phase 1 Studies of OP0201 OP0201 Was Safe and Well-Tolerated in Healthy Adults and Adults with Acute Otitis Media April 22, 2019 at 8:00 AM Eastern Time IRVINE, Calif. -- (BUSINESS WIRE) -- Novus Therapeutics, Inc. (NASDA
Read more →ELDNNovus Therapeutics Reports Fourth Quarter and Full-Year 2018 Financial Results and Provides Clinical Updates
Novus Therapeutics Reports Fourth Quarter and Full-Year 2018 Financial Results and Provides Clinical Updates March 28, 2019 at 8:00 AM Eastern Time IRVINE, Calif. -- (BUSINESS WIRE) -- Novus Therapeutics, Inc. (NASDAQ: NVUS), a specialty pharmaceutical company focused on develo
Read more →ELDNForward-Looking Statements This presentation contains forward looking statements that involves substantial risks and uncertainties. Any statements about the company's future expectations, plans and prospects, including s
Novus Investor Presentation Exhibit 99.1 Forward-Looking Statements This presentation contains forward looking statements that involves substantial risks and uncertainties. Any statements about the company's future expectations, plans and prospects, including statements about it
Read more →ELDNNovus Therapeutics Reports Third Quarter 2018 Financial Results
Novus Therapeutics Reports Third Quarter 2018 Financial Results November 13, 2018 at 8:00 AM Eastern Time IRVINE, Calif. -- (BUSINESS WIRE) -- Novus Therapeutics, Inc. (NASDAQ: NVUS), a specialty pharmaceutical company focused on developing products for patients with disorders
Read more →ELDNNovus Therapeutics Reports Second Quarter 2018 Financial Results
Novus Therapeutics Reports Second Quarter 2018 Financial Results August 7, 2018 at 8:30 AM Eastern Daylight Time IRVINE, Calif. -- (BUSINESS WIRE) -- Novus Therapeutics, Inc. (NASDAQ: NVUS), a specialty pharmaceutical company focused on developing products for patients with dis
Read more →ELDNNOVUS THERAPEUTICS, INC. CONSOLIDATED STATEMENTS OF OPERATIONS AND OTHER COMPREHENSIVE LOSS (In thousands, except share and per share data) Three Months Ended
Novus Therapeutics Reports First Quarter 2018 Financial Results Friday May 11, 2018 6:15 AM PDT IRVINE, Calif. -- (BUSINESS WIRE) -- Novus Therapeutics, Inc. (NASDAQ: NVUS), a specialty pharmaceutical company focused on developing products for patients with disorders of the ear
Read more →ELDNNOVUS THERAPEUTICS, INC. CONSOLIDATED STATEMENTS OF OPERATIONS AND OTHER COMPREHENSIVE LOSS (In thousands, except share and per share data) Year Ended
Novus Therapeutics Reports Fourth Quarter and Full-Year 2017 Financial Results and Provides Corporate Update Friday, March 30, 2018 2:00 pm PDT IRVINE, Calif. -- (BUSINESS WIRE) -- Novus Therapeutics, Inc. (NASDAQ: NVUS), a specialty pharmaceutical company focused on developing
Read more →ELDNForward-Looking Statements This presentation contains forward-looking statements that involves substantial risks and uncertainties. Any statements about the company's future expectations, plans and prospects, including s
Corporate Presentation November 29, 2017 Exhibit 99.1 Forward-Looking Statements This presentation contains forward-looking statements that involves substantial risks and uncertainties. Any statements about the company's future expectations, plans and prospects, including statem
Read more →ELDNNOVUS THERAPEUTICS, INC. CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) (In thousands) Nine Months Ended
Novus Therapeutics Reports Third Quarter 2017 Results IRVINE, Calif., Nov. 8, 2017 /PRNewswire/ -- Novus Therapeutics, Inc. (NASDAQ: NVUS), a development stage specialty pharmaceutical company focused on the development of products for disorders of the ear, nose, and throat (ENT
Read more →ELDNNovus Therapeutics Reports Second Quarter 2017 Results
Novus Therapeutics Reports Second Quarter 2017 Results IRVINE, Calif., August 9, 2017 /PRNewswire/ Novus Therapeutics, Inc. (NASDAQ: NVUS), a development stage specialty pharmaceutical company focused on the development of products for disorders of the ear, nose, and throat (EN
Read more →ELDNTokai Pharmaceuticals and Otic Pharma Enter into Share Purchase Agreement Transaction to create NASDAQ-listed pharmaceutical company focused on the development and commercialization of ear, nose, and throat (ENT) product
Tokai Pharmaceuticals and Otic Pharma Enter into Share Purchase Agreement Transaction to create NASDAQ-listed pharmaceutical company focused on the development and commercialization of ear, nose, and throat (ENT) products Gregory J. Flesher to be Named President and Chief Exec
Read more →ELDNAny statements contained in this presentation about our future expectations, plans and prospects, including statements about our strategy, future operations, intellectual property, cash resources, financial position and
Tokai Pharmaceuticals Corporate Overview January 2016 Exhibit 99.1 Any statements contained in this presentation about our future expectations, plans and prospects, including statements about our strategy, future operations, intellectual property, cash resources, financial pos
Read more →ELDNTokai Pharmaceuticals Announces the Appointment of Cheryl Cohen, Former Medivation Chief Commercial Officer, to its Board of Directors CAMBRIDGE, Mass. (BUSINESS WIRE)
Tokai Pharmaceuticals Announces the Appointment of Cheryl Cohen, Former Medivation Chief Commercial Officer, to its Board of Directors CAMBRIDGE, Mass. (BUSINESS WIRE) Apr. 13, 2015 Tokai Pharmaceuticals. Inc. (NASDAQ: TKAI), a clinical-stage biopharmaceutical company focused
Read more →ELDNTokai Pharmaceuticals Reports Fourth Quarter and Full Year 2014 Financial Results
Tokai Pharmaceuticals Reports Fourth Quarter and Full Year 2014 Financial Results CAMBRIDGE, Mass., March 12, 2015 Tokai Pharmaceuticals, Inc. (NASDAQ: TKAI), a clinical-stage biopharmaceutical company focused on developing novel therapies for prostate cancer and other hormonal
Read more →ELDNTokai Pharmaceuticals Provides Companion Diagnostic Update ARMOR3-SV Remains On-Track to Begin in the First Half of the Year CAMBRIDGE, Mass. (BUSINESS WIRE)
Tokai Pharmaceuticals Provides Companion Diagnostic Update ARMOR3-SV Remains On-Track to Begin in the First Half of the Year CAMBRIDGE, Mass. (BUSINESS WIRE) Jan. 12, 2015 Tokai Pharmaceuticals, Inc. (NASDAQ: TKAI), today announced that it has entered into an agreement with th
Read more →ELDNStephen Buckley, Jr. Appointed to Tokai Board of Directors CAMBRIDGE, Mass. (BUSINESS WIRE)
Stephen Buckley, Jr. Appointed to Tokai Board of Directors CAMBRIDGE, Mass. (BUSINESS WIRE) Jan. 9, 2015 Tokai Pharmaceuticals, Inc. (NASDAQ: TKAI), a clinical-stage biopharmaceutical company focused on developing novel therapies for prostate cancer and other hormonally driven
Read more →ELDNTokai Pharmaceuticals Reports Third Quarter 2014 Financial Results Company Successfully Completed Initial Public Offering
Tokai Pharmaceuticals Reports Third Quarter 2014 Financial Results Company Successfully Completed Initial Public Offering CAMBRIDGE, Mass., November 10, 2014 Tokai Pharmaceuticals, Inc. (NASDAQ: TKAI), a clinical-stage biopharmaceutical company focused on developing novel ther
Read more →Competitive Position
How ELDN ranks across every disease it competes inCompetitive Position is a premium feature
See how ELDN ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial